The Impact of Peptide Insertions on Adeno-Associated Viral Vector Fate by Uhrig, Silke
 The Impact of Peptide Insertions 










Erlangung des Doktorgrades 
Dr.nat.med. 
der Medizinischen Fakultät 
und 
der Mathematisch-Naturwissenschaftlichen Fakultät 












































Berichterstatter/-in: Prof. Dr. Herbert Pfister 
    Prof. Dr. Dagmar Knebel-Mörsdorf 
 
 






























Ihrer wahren Wesensbestimmung nach ist die Wissenschaft  
das Studium der Schönheit der Welt. 




Table of contents 
 
List of figures........................................................................................................................ IV 
List of tables .......................................................................................................................... V 
List of abbreviations .............................................................................................................. V 
Zusammenfassung................................................................................................................ 1 
Abstract ................................................................................................................................. 3 
1 Introduction .................................................................................................................... 4 
1.1 Gene therapy vectors .............................................................................................. 4 
1.1.1 Vector targeting by pseudotyping ...................................................................... 6 
1.1.2 Vector targeting using adaptors......................................................................... 8 
1.1.3 Genetic incorporation of targeting ligands ........................................................10 
1.1.4 AAV peptide display .........................................................................................12 
1.2 AAV and its infectious biology ................................................................................13 
1.3 Aim of the study .....................................................................................................18 
2 Materials and Methods ..................................................................................................19 
2.1 Materials ................................................................................................................19 
2.1.1 Chemicals, solutions and enzymes ..................................................................19 
2.1.2 Standard kits ....................................................................................................20 
2.1.3 Plasmids ..........................................................................................................20 
2.1.4 Primers ............................................................................................................22 
2.1.5 Single-stranded oligonucleotides......................................................................22 
2.1.6 Antibodies ........................................................................................................23 
2.1.6.1 Primary antibodies......................................................................................23 
2.1.6.2 Secondary antibodies .................................................................................23 
2.1.7 Bacteria strain ..................................................................................................23 
2.1.8 Eukaryotic cell lines..........................................................................................23 
2.1.9 Laboratory equipment and disposables............................................................24 
2.1.10 Data treating software ......................................................................................25 
2.2 Methods .................................................................................................................26 
2.2.1 Bacteria culture ................................................................................................26 
2.2.1.1 Cultivation of bacteria .................................................................................26 
2.2.1.2 Preparation of chemically competent bacteria ............................................26 
2.2.1.3 Transformation of bacteria..........................................................................26 
2.2.2 Working with nucleic acids ...............................................................................27 
2.2.2.1 Plasmid amplification and extraction...........................................................27 
2.2.2.2 DNA and RNA quantification ......................................................................27 
  II
2.2.2.3 Restriction enzyme digest...........................................................................27 
2.2.2.4 Agarose gel electrophoresis and gel extraction ..........................................27 
2.2.2.5 DNA extraction from animal cells................................................................28 
2.2.2.6 RNA extraction from animal cells and DNase I digest.................................28 
2.2.2.7 cDNA synthesis ..........................................................................................28 
2.2.2.8 Polymerase chain reaction (PCR)...............................................................28 
2.2.2.9 Quantitative PCR (qPCR)...........................................................................29 
2.2.2.10 Sequencing ................................................................................................31 
2.2.2.11 Molecular Cloning.......................................................................................31 
2.2.2.11.1 Cloning amplified viral DNA ................................................................31 
2.2.2.11.2 Re-cloning viral insertion sequences...................................................31 
2.2.2.11.3 Cloning GFP-tagged rAAV peptide insertion mutants .........................32 
2.2.3 Working with proteins.......................................................................................32 
2.2.3.1 Protein extraction from HeLa cells ..............................................................32 
2.2.3.2 Acetone precipitation of proteins ................................................................32 
2.2.3.3 Western Blot...............................................................................................33 
2.2.3.4 ELISA.........................................................................................................34 
2.2.4 Eukaryotic cell culture ......................................................................................35 
2.2.4.1 Cultivation of cells ......................................................................................35 
2.2.4.2 Drug treatment ...........................................................................................35 
2.2.4.3 Trypsin treatment .......................................................................................36 
2.2.4.4 Counting, seeding and passaging...............................................................36 
2.2.4.5 Freezing and thawing cells .........................................................................36 
2.2.4.6 DAPI staining..............................................................................................36 
2.2.5 Vector production and purification ....................................................................37 
2.2.5.1 AAV vector packaging ................................................................................37 
2.2.5.2 Iodixanol gradient purification .....................................................................37 
2.2.5.3 Vector titration ............................................................................................38 
2.2.6 Selection of rAAV peptide insertion mutants.....................................................38 
2.2.6.1 Heparin affinity chromatography.................................................................38 
2.2.6.2 Selection of rAAV peptide insertion mutants on K-562 cells........................39 
2.2.7 Cell transduction by rAAV vectors ....................................................................39 
2.2.7.1 Quantification of vector entry efficiency ......................................................39 
2.2.7.2 Quantification of vector genome transcripts................................................39 
2.2.7.3 Cell transduction assay ..............................................................................40 
2.2.7.4 Heparin competition assay .........................................................................40 
2.2.7.5 Quantification of vector genomes in subcellular fractions ...........................40 
  III
2.2.7.6 Immunoflourescence assay of fluorescent-protein-tagged rAAV vectors ....41 
2.2.8 Statistical analysis............................................................................................42 
3 Results ..........................................................................................................................43 
3.1 Selection of AAV peptide insertion mutants on K-562 cells.....................................43 
3.2 Characterization of rAAV peptide insertion mutants regarding cell entry.................46 
3.2.1 Analysis of primary receptor binding ability by Heparin competition..................46 
3.2.2 Inhibition of clathrin-mediated endocytosis by Chlorpromazine ........................49 
3.2.3 Inhibition of caveolar endocytosis by Genistein ................................................51 
3.2.4 Combining Heparin competition and inhibition of clathrin-mediated endocytosis 
by Chlorpromazine ...........................................................................................52 
3.2.5 Determination of cell entry efficiency ................................................................53 
3.3 Genetic fluorescence labelling of rAAV peptide insertion mutants ..........................57 
3.4 Characterization of rAAV peptide insertion mutants with respect to intracellular 
events ...........................................................................................................................61 
3.4.1 Adjustment of  intracellular vector particles ......................................................61 
3.4.2 Transduction efficiencies of rAAV vectors with adjusted intracellular particles..64 
3.4.3 Proteasome inhibition by MG-132 ....................................................................66 
3.4.4 Quantification of vector genome transcripts......................................................67 
3.4.5 Subcellular distribution of rAAV vectors............................................................70 
3.4.6 Inhibition of endosomal maturation by Bafilomycin ...........................................72 
4 Discussion.....................................................................................................................74 
4.1 Vector-cell interactions at the plasma membrane ...................................................74 
4.2 Intracellular vector fate ...........................................................................................79 




List of figures 
 
Figure 1: Entry mechanisms of unmodified viral vectors ........................................................ 5 
Figure 2: Pseudotyping viral vectors...................................................................................... 7 
Figure 3: Vector targeting using adaptors.............................................................................. 9 
Figure 4: Genetic targeting ...................................................................................................12 
Figure 5: AAV peptide display ..............................................................................................13 
Figure 6: Capsid and genome structure of AAV2..................................................................14 
Figure 7: Current model of AAV2 infection in HeLa cells ......................................................17 
Figure 8: Transduction efficiencies of rAAV2 and rAAV peptide insertion mutants in the 
presence or absence of soluble Heparin ..............................................................................47 
Figure 9: Inhibition of cell transduction by HSPG-binder vectors in the presence of increasing 
concentrations of Heparin.....................................................................................................48 
Figure 10: Transduction efficiencies in the presence or absence of Chlorpromazine............50 
Figure 11: Transduction efficiencies in the presence or absence of Genistein......................51 
Figure 12: Transduction efficiencies in the presence of Chlorpromazine, Heparin, 
Chlorpromazine and Heparin or in the absence of the substances .......................................53 
Figure 13: Cell entry efficiencies of rAAV vectors into different cell lines ..............................54 
Figure 14: Cell entry efficiencies of rAAV2 and rAAV peptide insertion mutants ...................56 
Figure 15: Western blot analysis of GFP-tagged insertion mutants and mCherry-tagged 
rAAV2...................................................................................................................................58 
Figure 16: Evaluation of GFP-tagged peptide insertion mutants and mCherry-tagged rAAV2
.............................................................................................................................................59 
Figure 17: Intracellular localization of GFP-tagged B1, GFP-tagged C2 and mCherry-tagged 
rAAV2 after single or co-transduction ...................................................................................61 
Figure 18: Adjustment of intracellular vector particles...........................................................63 
Figure 19: Transduction efficiencies of rAAV vectors with adjusted intracellular genomic 
particles................................................................................................................................65 
Figure 20: Transduction efficiencies in the presence or absence of MG-132 ........................67 
Figure 21: Quantification of vector genome transcripts depending on time...........................69 
Figure 22: Subcellular distribution of rAAV2 and HSPG-binder mutants in cellular membranes 
and nuclei.............................................................................................................................71 
Figure 23: Transduction efficiencies of rAAV2 and HSPG-binder mutants in the presence or 
absence of Bafilomycin.........................................................................................................73 
Figure 24: Model for the uptake of rAAV2 and rAAV peptide insertion mutants and the 
intracellular consequences ...................................................................................................86 
 
  V 
List of tables 
 
Table 1: Overview of the selection procedure.......................................................................44 
Table 2: Sequences in HSPG-non-binder and HSPG-binder pool after the third selection 
round....................................................................................................................................44 
Table 3: Characterization of vector preparations ..................................................................46 
Table 4: Characterization of vector preparations: mCherry-tagged rAAV2 and GFP-tagged 
peptide insertion mutants .....................................................................................................57 
Table 5: Calculation of intracellular genomic particles (i.g.p.) based on cell entry efficiency 1h 
post transduction ..................................................................................................................62 
Table 6: Statistical analysis for transduction efficiencies of rAAV vectors with adjusted 
intracellular genomic particles ..............................................................................................65 
Table 7: Subcellular distribution of rAAV vector genomes 2h post transduction....................70 
 
 
List of abbreviations 
aa amino acid 
AAV adeno-associated virus 
AAVS1 AAV integration site 1 
Ad adenovirus 
AlasI δ-aminolevulinate synthase I 
ALV avian leucosis virus 
ApoE apolipoprotein E 
APS ammonium persulfate  
ATP adenosine triphosphate 
B-CLL B cell chronic lymphocytic leukemia 
bp base pair 
CAR coxsackie and adenovirus receptor 
CD cluster of differentiation 
cDNA complementary DNA 
CPZ chlorpromazine 
Cy5 cyanine 5 
DAPI 4′,6-diamidino-2-phenylindol 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DOC deoxycholic acid 
DTT dithiothreitol 
  VI
EDTA ethylenediaminetetraacetic acid  
e.g. lat. exempli gratia (“for example”) 
EGF(R) epidermal growth factor (receptor) 
ELISA enzyme-linked immunosorbent assay 
EPO erythropoietin 
FACS fluorescence activated cell sorting 
FCS fetal calf serum 
FGF(R) fibroblast growth factor (receptor) 
FITC fluorescein-5-isocyanate 
g.p. genomic particles 
GFP green fluorescent protein 
gp glycoprotein 
HGF(R) hepatocyte growth factor (receptor) 
HIV human immunodeficiency virus 
HLA human leucocyte antigen 
HRP horseraddish peroxidase 
HSPG heparan sulphate proteoglycan 
i.e. lat. id est (“that is”) 
IGF insulin-like growth factor 
i.g.p. intracellular genomic particles 
ITR inverted terminal repeat 
kb kilo bases 
LamR laminin receptor 
LB Luria-Bertani 
LDL(R) low-density lipoprotein (receptor) 
LH luteinizing hormone 
MG-132 carbobenzoxy-Leu-Leu-leucinal 
MLV murine leukemia virus 
NPC nuclear pore complex 
nt nucleotide 
OD optical density 
ORF open reading frame 
p.i. post infection 
p.t. post transduction 
PAGE polyacrylamid gel electrophoresis 
PBS phosphate buffered saline 
PCR polymerase chain reaction 





PI3K phosphatidylinositol-3 kinase 
PIPES piperazine-N,N′-bis(2-ethanesulfonic acid) 
PLA2 phospholipase A2 
Plat plasminogen activator 
qPCR quantitative PCR 
rAAV recombinant adeno-associated viral vector 
Rab Ras-related in brain 
Rac1 Ras-related C3 botulinum toxin substrate 1 
RIPA radioimmunoprecipitation assay 
RNA ribonucleic acid 
RT-PCR reverse transcriptase PCR 
scFv single-chain fragment of variable region 
SDS sodium dodecyl sulphate 
TBE tris borate EDTA 
TEMED N,N,N,N-tetramethylethylenediamine 
TMB 3,3’, 5,5’-tetramethylbenzidine 
Tris tris(hydroxymethyl)aminomethane 
VAP viral attachment protein 
VP viral protein 
VSV vesicular stomatitis virus 
 
 
Commonly used abbreviations and SI units are not separately listed. 
 
  1 
Zusammenfassung 
 
Rekombinante Adeno-assoziierte virale (rAAV) Vektoren besitzen eine Reihe für einen 
Vektor vorteilhafter Eigenschaften, darunter sind eine geringe Immunogenität, hohe 
Stabilität, langlebige Transgenexpression und das Potential zur ortsspezifischen Integration 
ohne bisher bekannte Nebenwirkungen zu nennen. Der Einsatz von rAAV-Vektoren in der 
Gentherapie wird jedoch dadurch limitiert, dass AAV einen breiten Gewebetropismus 
aufweist, der zu einer unerwünschten Transduktion von Nicht-Zielzellen führen kann. 
Kürzlich wurde demonstriert, dass die genetische Modifizierung des AAV-Kapsids durch 
Insertion rezeptorspezifischer Liganden („AAV targeting“) die Transduktion von Zellen 
unabhängig vom Vorhandensein der natürlichen AAV-Rezeptoren ermöglicht. Die „AAV-
targeting“-Technologie führt darüber hinaus zu einer Erhöhung der Transduktionseffizienz 
auf Wildtyp-AAV-permissiven Zellen und bietet die Möglichkeit zu einem AAV-vermittelten, 
zelltypspezifischen Gentransfer.  
Die vorliegende Arbeit zeigt erstmals, dass der inserierte Ligand sowohl den Mechanismus 
der Internalisierung des AAV-Vektors bestimmt, als auch die Effizienz, mit der Vektoren in 
die Zelle und Vektorgenome in den Zellkern übertragen werden. Mit Hilfe von „AAV peptide 
display“ wurden vier rAAV-Peptidinsertionsmutanten selektiert, die sich in der inserierten 
Sequenz und der Nettoladung der Insertion unterscheiden, und im Hinblick auf ihre Vektor-
Zell Interaktion im Vergleich zu rAAV2 analysiert. Mutanten (A2 und C2) mit neutralen 
Peptidliganden transduzierten Zellen unabhängig vom AAV2-Primärrezeptor Heparansulfat-
Proteoglykan (HSPG), während die Affinität der Mutanten B1 und D5 zu HSPG mit der 
positiven Nettoladung Ihrer Liganden korrelierte. Im Vergleich zu rAAV2 wies B1 eine 
niedrigere Affinität zu HSPG auf, D5 hingegen eine wesentlich höhere. Die neue Liganden-
Rezeptor Interaktion führte zu einer Clathrin-vermittelten Aufnahme von A2 und C2, während 
D5 auf einem Clathrin-unabhängigen Weg in die Zelle eintrat – vermutlich über HSPG. 
Obwohl sich B1 nur in einer Aminosäure von C2 unterscheidet, war B1 in der Lage, sowohl 
Clathrin-vermittelt, als auch Clathrin-unabhängig in die Zelle aufgenommen zu werden. 
Vermittelt durch ihre Fähigkeit, an HSPG zu binden, traten B1 und D5 – im Gegensatz zu A2 
und C2 – effizient in verschiedene Zelltypen ein. Effiziente Transgenexpression war 
hingegen von der Aufnahme der AAV-Vektoren über Clathrin-vermittelte Endozytose 
abhängig. Während die Transgenexpression bei allen AAV-Vektoren zu einem ähnlichen 
Zeitpunkt begann, erreichten Clathrin-vermittelt internalisierte Vektoren (rAAV2, A2 und C2) 
ein sigifikant höheres Genexpressionsniveau, was vermuten lässt, dass dieser 
Eintrittsmechanismus für eine effiziente intrazelluläre Prozessierung ausschlaggebend ist. In 
Übereinstimmung mit diesem Ergebnis wurden von B1 und D5, die Clathrin-unabhängig in 
die Zelle gelangten, signifikant weniger Vektorgenome in den Kern übertragen, als von 
  2 
rAAV2. Statt dessen waren die Vektorgenome von B1 und D5 hauptsächlich mit 
membranumhüllten Zellorganellen – vermutlich Endosomen – assoziiert, was vermuten lässt, 
dass die intrazelluläre Prozessierung von Vektoren nach Proteoglykan-abhängiger 
Internalisierung im Vergleich zur effizienten Prozessierung von rAAV2 beeinträchtigt ist. 
  3 
Abstract 
 
Recombinant adeno-associated viral (rAAV) vectors possess a number of attractive 
properties including low immunogenicity, high stability, longevity of transgene expression and 
the potential to integrate site-specifically without known side-effects. The major limitation 
regarding the use of AAV vectors for gene therapy is the broad tissue tropism of AAV 
following in vivo gene tranfer application. Recently, genetic modification of the AAV capsid by 
insertion of receptor-specific ligands (AAV targeting) was demonstrated to enable the 
transduction of cells in the absence of AAV’s natural receptors, to improve transduction 
efficiency in wild-type-AAV-permissive cells and to provide the opportunity of rAAV-mediated, 
cell-type-specific gene transfer. 
This study shows for the first time, that the inserted ligand both alters the mechanism of AAV 
vector internalization and determines the efficiency of cell entry and nuclear delivery of vector 
genomes. Using AAV peptide display, four rAAV peptide insertion mutants differing in 
sequence and net charge of the inserted ligand were selected and analyzed regarding their 
vector-cell interplay in comparison to rAAV2. Mutants (A2 and C2) displaying neutral peptide 
ligands transduced cells independent of AAV2’s primary receptor heparan sulphate 
proteoglycan (HSPG), whereas the affinity of the mutants B1 and D5 to HSPG correlated 
with the net positive charge of their ligands. Compared to rAAV2, the affinity to HSPG was 
lower for B1, but notably higher for D5. Ligand-receptor interaction led to clathrin-dependent 
uptake of A2 and C2, while D5 entered cells clathrin-independently, presumably via HSPG. 
Interestingly, B1, differing in a single amino acid from C2, was able to use both entry routes. 
Mediated by their ability to bind to HSPG, B1 and D5 – in contrast to A2 and C2 – entered 
efficiently into different cell lines. However, efficient transgene expression was dependent on 
vector entry by clathrin-mediated endocytosis. While the onset of gene expression happened 
in a similar time frame for all AAV vectors, those vectors internalized in a clathrin-mediated 
fashion (rAAV2, A2 and C2) reached significantly higher gene expression levels, 
demonstrating that this entry route is pivotal for efficient intracellular processing. In line with 
this observation, B1 and D5 – which entered the cell clathrin-independently – delivered 
significantly less vector genomes to the nucleus than rAAV2, but were mostly present inside 
membrane-coated cellular compartments – most likely inside endosomes – revealing that 
vector trafficking following proteoglycan-dependent endocytosis is impaired compared to the 







1.1 Gene therapy vectors 
Gene therapy can be defined as the use of genetic material to modify a patient's cells for the 
treatment of an inherited or acquired disease. In general, a gene must be delivered to the cell 
using a carrier, or vector. The vector systems currently used in gene therapy can be divided 
into viral and non-viral vectors. Since viruses have evolved specialized molecular 
mechanisms to efficiently transport their genomes into cells, they possess ideal 
characteristics as a gene transfer vehicle. Indeed, the most common type of vectors used 
today is based on virions that have been genetically altered to carry a transgene instead of 
their viral genome and are termed viral vectors. Such a viral vector can transduce cells and 
deliver its transgene but does not produce progeny, which is a key property regarding vector 
safety. The most popular viral gene therapy vectors are based on retro/lentiviruses, 
adenoviruses (Ad) and adeno-associated virus (AAV), which have different mechanisms to 
enter a host cell [1] (Figure 1). 
Ad is a non-enveloped, double-stranded DNA virus with an icosahedral capsid consisting of 
hexon (240 trimers), fiber (12 monomers) and penton (5 pentamers) [2]. Fiber and penton 
mediate binding to cell surface receptors followed by internalization. The uptake of Ad 
serotype 5, a common platform of Ad-based vectors, involves the attachment of Ad5 to the 
coxsackie and adenovirus receptor (CAR), conducted by the fiber knob, followed by 
interactions between penton base components and αv integrins leading to internalization of 
Ad5 [3],[4] (Figure 1a). 
AAV is a non-enveloped virus with a single-stranded DNA genome. The icosahedral capsid 
of AAV is built by 60 monomers of the three viral proteins VP1, VP2 and VP3 in a ratio of 
~1:1:10 [5]. Similar to Ad, the AAV capsid mediates binding to cellular attachment and 
internalization receptors. AAV serotype 2, the best characterized AAV serotype and a 
promising vector platform, makes its first contact with the cell by attaching to the primary 
receptor HSPG, which might be enhanced by co-receptors such as fibroblast growth factor 
receptor (FGFR) and/or hepatocyte growth factor receptor (HGFR) [6],[7]. Subsequent 
binding to integrins leads to endocytosis of AAV2 via clathrin-coated pits [8-11] (Figure 1b). 
In addition to clathrin-mediated endocytosis, caveolin-dependent uptake is involved in the 
uptake of AAV serotype 5, which binds to the cell via sialic acid and platelet-derived growth 
factor receptor (PDGFR) [12-15].  
Retro-/lentiviruses are enveloped viruses with a diploid single-stranded, positive sense RNA 
genome [1]. The viral genome is surrounded by a protein shell, the nucleocapsid, and a lipid 




step in lentiviral cell entry is a fusion between the viral envelope and the cellular membrane 
mediated by Env proteins [16] (Figure 1c). HIV entry into target cells, for example, is 
mediated by the viral Env proteins gp120 and gp41 upon binding to the cellular CD4 
molecule and a co-receptor on the target cell plasma membrane. Subsequent conformational 
changes in gp41 bring the viral and cellular membranes in close proximity and allow fusion 
pore formation. Finally, the nucleocapsid is released to the cytosol [1],[16]. 
 
 
Figure 1: Entry mechanisms of unmodified viral vectors 
a: Adenovirus (Ad): Ad serotype 5 binds to its receptor CAR (coxsackie and adenovirus receptor) 
through its fiber knob. Subsequently, integrins interact with the RGD peptide motif in the penton base 
and facilitate cell entry by endocytosis. 
b: Adeno-associated virus (AAV): Several residues of the AAV2 (adeno-associated virus serotype 2) 
capsid are involved in binding to heparan sulphate proteoglycan (HSPG) and then to the co-receptors, 
which can be integrins (shown here), FGFR, HGFR or others. Subsequently, the virus is internalized 
by endocytosis. 
c: Retrovirus (lentivirus): Membrane fusion is the main mechanism whereby enveloped viruses deliver 
their genomes into target cells. After initial non-specific adhesion of the virus to the cell surface, viral 
attachment glycoproteins bind specifically to their cognate receptors, whereupon binding becomes 
irreversible. Subsequent steps in the viral entry process vary between different viruses but always 
result in fusion between the lipid membranes of the virus and the host cell, following which the viral 
nucleocapsid is released into the cytoplasm. In most cases, receptor binding triggers conformational 
changes in the viral proteins that mediate membrane fusion. SU, surface subunit; TM, transmembrane 
subunit. Reprinted by permission of Macmillan Publishers Ltd: Nature Reviews Genetics [3], © 2007 
 
 
Besides viral vectors, non-viral systems – usually a polymer-DNA or lipid-DNA complex – 
have been used to deliver exogenous DNA into cells. Cationic polymers and lipids interact 




lipoplexes, respectively [17]. Cationic carriers were shown to bind to cell surface HSPGs and 
enter the cell by endocytosis or phagocytosis followed by endosomal trafficking of the DNA-
containing complex [18-23]. Cationic lipoplexes can deliver the complexed DNA into the 
cytoplasm by de-stabilizing the endosomal membrane (“flip-flop” of anionic lipids) [24],[25], 
whereas the ionizable amine groups of cationic polymers are able to cause osmotic swelling 
and rupture of the endosomal membrane (“proton-sponge” hypothesis) [26]. Advantages 
associated with these kinds of vectors include their large-scale manufacture, their low 
immunogenecity and the capacity to carry large DNA molecules [17],[27]. However, 
compared to viral vectors, non-viral vectors are still less efficient with respect to transgene 
expression, i.e. successful cell transduction [1],[17]. 
 
Despite the ability of efficient gene delivery at least into certain cell types, there are still 
numerous problems regarding the use of viral vectors for gene therapy. To achieve 
therapeutic success, gene transfer vehicles not only have to mediate efficient gene delivery 
and expression, but they also have to be capable of transducing target cells without harming 
non-target cells. The first drawback associated with unmodified viral vectors is the inefficient 
transduction of therapeutically relevant cell types, while the second is caused by the tropism 
of natural viral variants that is not restricted to certain cells or tissues. Hence, to achieve 
efficient and specific gene transfer in vivo, novel viral vectors with user-defined gene delivery 
properties have to be developed. 
Several techniques have been utilized in viral vector engineering which modify the viral 
capsid or envelope, among them pseudotyping, the use of adaptors and genetic targeting 
approaches [3]. 
 
1.1.1 Vector targeting by pseudotyping 
A major limitation of gene therapy approaches is the poor transduction of therapeutically 
relevant cell types caused by the absence of receptors for viral attachment proteins (VAPs) 
[28],[29]. This constraint can be circumvented by pseudotyping, a technique involving the 
transfer of VAPs between different viral serotypes, thereby broadening the viral tropism. In 
addition, mosaic or chimeric vectors can be built by mixing VAPs from different variants or by 
swapping smaller VAP domains between serotypes [1].  
Pseudotyping has most extensively been used to modulate the tropism of lentiviral vectors 
because they are highly permissive for incorporation of heterologous attachment 
glycoproteins into their lipid envelope [30],[31] (Figure 2A). The use of VSV-G (the 
glycoprotein of vesicular stomatitis virus) or Env proteins of γ-retroviruses as VAPs in a 
pseudotyped lentiviral vector confers a broad tropism, making it possible to achieve gene 




Pseudotyping has also been used for the non-enveloped vectors Ad and AAV, where the 
VAP must be incorporated into a protein capsid instead of a lipid bilayer (Figure 2B and C). 
Chimeric Ad particles, generated by exchanging fibers or hexons between Ad5 and other 
serotypes, have the potential to alter the viral tropism. Fibers from different serotypes in the 
context of the Ad5 capsid were shown to improve transduction of some cancer and primary 
cell lines [34],[35], and chimeric Ad vectors with fiber-like proteins from T4 bacteriophage or 
reovirus could be targeted to alternate receptors [36],[37].  
Pseudotyped or pseudopackaged AAV vectors can be generated by packaging vector 
genomes flanked by the AAV2-ITR sequences into capsids of a different serotype [7]. 
Chimeric and mosaic AAV vectors are built by swapping capsid monomers or domains from 
one serotype to another, thereby generating vectors with the combined gene delivery 
properties of the parent serotypes [38-40]. For example, an AAV1/AAV2 chimeric vector 
achieved gene expression levels similar to those of AAV1 in muscle and AAV2 in liver, and 
could be purified by heparin affinity chromatography like wild-type AAV2 [38]. An AAV3/AAV5 
mosaic vector was shown to share both receptor binding abilities of the parent serotypes, as 
it could bind to heparan sulphate (like AAV3) and mucin (like AAV5) [39]. Moreover, vectors 
composed of various monomeric capsid proteins or capsid domains from different serotypes 
gained novel functions not found among natural variants [39-42].  
Pseudotyped viral vectors have an expanded tropism to cell types that are refractory to the 
natural variant. However, de-targeting from the natural tropism often needs further 
modifications of the pseudotyped vector that require structural knowledge of the VAP. 
 
 
Figure 2: Pseudotyping viral vectors 
A retroviral/lentiviral vector is pseudotyped with an envelope protein (Env) from a different virus (A). 
Pseudotyping of adenoviral vectors is achieved by exchanging fibers or hexons between different 
serotypes (B). AAV can be pseudotyped by swapping capsid proteins or capsid protein domains 
between different serotypes (C). Adapted by permission of Macmillan Publishers Ltd: Nature Reviews 
Genetics [3], © 2007 





1.1.2 Vector targeting using adaptors 
The use of adaptor proteins has been explored as a technique that is applicable even with 
limited knowledge of the viral structure [3]. Adaptors are molecules with dual specificities: 
one end binds to the viral vector and the other end binds to the receptor on the target cell. 
The advantage of this approach is the ability to change viral properties in a highly modular 
manner and that most adaptors can achieve the two main goals of targeted delivery: ablating 
native tropism and conferring a novel tropism towards the desired target [3].  
Bi-specific linker molecules have commonly been applied to retroviral vector systems. 
Typically, the adaptors are fusion proteins composed of a viral receptor, which interacts with 
the vector particle via the Env protein, and a targeting ligand, which interacts with its cognate 
receptor on the target cells [1] (Figure 3A). Two adaptors composed of EGF and either avian 
leucosis virus A (ALV-A) receptor (TVA) or ALV-B receptor (TVB) achieved efficient ALV-A- 
or ALV-B-mediated transduction of cells expressing EGFR [43]. In a more complex linker 
approach, the protein A IgG-binding ZZ domain from Staphylococcus aureus [44] was 
inserted into the receptor binding site of Sindbis virus E2 Env protein [45],[46]. This allowed 
for example the incorporation of targeting antibodies against CD4 or human leukocyte 
antigen (HLA) into virus particles leading to preferential transduction of CD4+ and HLA+ cells 
by the re-targeted, pseudotyped retroviral vectors [45].  
Different bi-specific adaptors have been developed for targeting Ad vectors (Figure 3B). 
Fusion of the CAR ectodomain with EGF reduced vector binding to CAR+ cells by 90% and 
enhanced transduction of EGFR-expressing cells by the targeted vector up to 12-fold 
compared to an untargeted Ad [47]. Likewise, fusing the ectodomain of CAR with CD40 
ligand successfully targeted Ad vectors to dendritic cells expressing CD40 [48]. Chemical 
conjugation is a method for coupling adaptors to vectors in which the targeting ligand is 
covalently linked to the vector. Polyethylene glycol (PEG) has been used to couple Ad 
vectors to ligands such as FGF2 or an RGD-containing peptide in order to target ovarian 
cancer cells or endothelial cells [49], [50]. An extension of the chemical conjugation approach 
combines the flexibility of adaptor systems with the advantage of stable covalent bonds that 
are provided by genetic targeting (see below). Reactive thiol groups were introduced into the 
Ad capsid by genetically inserting cysteines at exposed positions. The thiol groups were then 
coupled to transferrin, which mediated the successful targeting of the vector to cells 
expressing transferrin receptor [51].  
Chemical coupling methods have also been developed through biotinylation of the AAV 
capsid. Streptavidin-EGF and Streptavidin-FGF fusion proteins mediated increased 
transduction of EGFR+ or FGFR+ cells by the targeted AAV vectors but no difference was 




indicating that the modified vector had retained its natural tropism. Also bi-specific adaptors 
have been studied: a bi-specific antibody that recognizes both the intact AAV2 capsid and 
αIIbβ3 integrin has been used to re-target AAV2 (Figure 3C). This vector demonstrated 
enhanced binding to wtAAV2-non-permissive cells and increased transduction up to 70-fold 
on these cell lines [53]. In an approach of combining genetic peptide insertion (see below) 
and the use of an adaptor, the protein A IgG-binding domain from S. aureus was genetically 
introduced into the AAV capsid and coupled to antibodies against CD29, CD117 and CXCR4 
leading to specific transduction of human hematopoietic cell lines, however with low 
efficiency [54] (Figure 3D). 
 
 
Figure 3: Vector targeting using adaptors 
Adaptors consist of a receptor-ligand fusion protein that binds to the VAP of the viral vector (the Env 
protein of a retro-/lentiviral vector (A) or the fiber knob of an adenoviral vector (B)) and to the 
respective receptor on the target cell. AAV is attached to a bi-specific antibody that recognizes both, 
the AAV capsid and a cellular receptor (C). An antibody-binding domain is genetically incorporated into 
the AAV capsid to couple a monoclonal antibody to the vector (D). Adapted by permission of 
Macmillan Publishers Ltd: Nature Reviews Genetics [3], © 2007 
 
 
Coupling of targeting molecules is not limited to viral vectors but is also of great interest to 
the targeted delivery of non-viral vectors [55]. Similar to non-enveloped viruses, cationic 
polyplexes and lipoplexes can be taken up into the cell in endocytic or phagocytic vesicles 
[17]. Clathrin- and caveolin-mediated endocytosis as well as an entry process independent of 
clathrin and caveolin has been proposed for the internalization of non-viral vectors [56-58]. 
However, efficient gene delivery using non-viral vectors is impeded by the entrapment of 
DNA complexes in the endosomal compartment leading to degradation of the internalized 
DNA [18],[57]. An improvement in endosomal escape was achieved by the use of 
polyethylenimine (PEI), a cationic polymer that condenses DNA and offers an intrinsic 
mechanism enabling the release of endocytosed DNA into the cytoplasm [59]. Coupling of 
targeting ligands to DNA/PEI polyplexes led to further increase in efficiency and cell-type-




specific gene transfer [60-66]. These ligands can be small molecules (galactose, mannose or 
EGF) or peptides/proteins (transferrin or antibodies). Incorporation of EGF or transferrin into 
the DNA/PEI complex resulted in both receptor targeting and receptor-mediated endocytosis, 
enabling greatly enhanced gene delivery [60],[61],[67]. Specific antibodies for certain cell 
surface markers have also been used for targeting: antibodies against CD3 or ErbB2 
enabled efficient gene delivery into human T-cell leukaemia cells (CD3+) or ErbB2+ human 
breast cancer cells [60],[68]. 
 
1.1.3 Genetic incorporation of targeting ligands 
Although targeting approaches using adaptors achieved cell-type-specific targeting, there is 
the potential risk that the affinity of vector-adaptor complexes in vivo may not be sufficient to 
prevent dissociation of the adaptor-vector linkage which might result in side-effects [3],[1]. 
Thus, methods were developed for the genetic incorporation of targeting ligands into viral 
vectors. Genetic fusion of these ligands into the capsid or Env protein yields a stable 
modification that can direct the virion to its target cell [3]. 
Various targeting molecules such as short peptides and single-chain antibody fragments 
(scFv) have been inserted into retroviral Env proteins (Figure 4A). Short targeting peptides 
inserted into Env proteins have been shown to mediate targeted gene delivery without 
severely disrupting the envelope’s function: upon insertion of RGD-containing motives, 
retroviral vectors could be targeted to human melanoma cells while the natural tropism of the 
vector was altered depending on the position of the inserted ligand [69]. Also the display of 
scFv on the surface of enveloped viruses was successfully accomplished by genetically 
fusing an antibody fragment to the surface component of Env glycoproteins. Retroviral 
vectors incorporating an anti-hapten antibody were shown to bind to hapten via the displayed 
antibody and vectors with an inserted low-density lipoprotein receptor (LDLR)-specific scFv 
could mediate a specific retroviral transduction of cells expressing LDLR [70],[71]. To reduce 
non-specific transduction of human cells, ecotropic MLV Env proteins have often been used 
as scaffold for the insertion of the scFv targeting domains [72]. In addition to peptides and 
single-chain antibodies, various ligands such as insulin-like growth factor I (IGF-1), EGF and 
erythropoietin (EPO) have been fused to Env proteins [73-76]. However, both, the 
incorporation of large scFv molecules and the insertion of ligands to the N-terminus of Env 
proteins, can interfere with the conformational changes required for Env proteins to mediate 
membrane fusion, resulting in low transduction efficiencies [75]. In particular, virus particles 
complexed with the targeted receptors were often sequestered on the cell surface or routed 
to degradative pathways after endocytosis [73],[76].  
Most peptide modification approaches for Ad5 have focused on the fiber (Figure 4B). 




pK7, mediating attachment to heparan sulphates, yielded infectious viral vectors that bound 
to the respective targets [77]. Also the insertion of peptide epitopes into the HI loop of the Ad 
fiber has been investigated. Insertion of an RGD-containing peptide conferred targeted gene 
delivery to cells expressing high levels of integrins [78]. Further developments demonstrated 
that insertion of both RGD and pK7 peptides into the fiber provides an additive effect of both 
functionalities and that the insertion of targeting peptides can lead to an ablation of native 
tropism [79],[80]. The incorporation of scFv molecules into an Ad vector was initially impeded 
because of the different biosynthetic pathways that are used to produce the scFv (which is 
synthesized in the rough endoplasmic reticulum) and the Ad capsid proteins (which are 
synthesized in the cytosol) [81]. In addition, incorporation of such large proteins into the Ad 
fiber can impede proper folding (trimerization) of the fiber [3]. The use of cytosolically 
stabilized scFvs (intrabodies) and the generation of an artificial fiber allowed genetic coupling 
of the fiber and scFv in the Ad system, which additionally gave rise to the advantage of 
ablating the native tropism of Ad [82]. 
Several sites of the AAV capsid were shown to tolerate the insertion of peptides but only 
some of these sites have been examined for their suitability in AAV vector targeting [83-88] 
(Figure 4C). The first attempt used an scFv molecule fused to the N-terminus of VP2 to 
target CD34+ cells but the overall transduction level remained low [89]. The incorporation of 
several smaller peptides, e.g. serpin receptor ligand, ApoE or an LH peptide, to the N-
terminus of VP1 or VP2 yielded functional virions and could expand the tropism of AAV2 [83-
85],[90],[91]. In two of these studies, the fusion of GFP to the N-terminus of VP2 gave rise to 
GFP-tagged viruses that have been used to visualize the infectious pathway of AAV [90],[91].  
Genetic capsid modification by insertion of peptides into the common region of all three AAV 
capsid proteins (amino acid position 587 and 588) could successfully re-target AAV2 
[86],[92]. These two positions have been used most frequently for the insertion of small 
peptides [86],[92-100], leading to superior ligand-mediated transduction of target cells by the 
capsid-modified AAV vectors. Insertions at the position 587 interfere with the binding of two 
(R585 and R588) of the five positively charged amino acids of the AAV2 HSPG-binding motif 
[101],[102], explaining the ablation of HSPG binding of some re-targeted vectors 
[54],[86],[93-95]. In some cases, binding was only partially affected or even restored, when 
ligands were inserted at amino acid position 587 [94],[95],[97],[100]. This loss or 
maintenance of HSPG binding was shown to depend on the nature of the inserted ligand 
sequence: Insertion of bulky or negatively charged peptides results in AAV2 capsid mutants 
unable to bind to HSPG due to sterical or charge interference. Insertion of positively charged 
peptides, however, can lead to an HSPG-binding phenotype by reconstituting a binding motif 






Figure 4: Genetic targeting 
Small targeting ligands are genetically inserted into the Env protein of a retro-/lentiviral vector (A), into 
the fiber knob domain of adenoviral vectors (B) or into the capsid protein of AAV (C) to target the viral 
vectors to distinct cellular receptors. The incorporation of RGD-containing peptides, for example, is 
used to specifically target integrin receptors. Adapted by permission of Macmillan Publishers Ltd: 
Nature Reviews Genetics [3], © 2007 
 
 
1.1.4 AAV peptide display 
Although rational modification techniques have generated viral vectors with novel gene 
delivery properties, the successful application of these approaches often requires detailed 
mechanistic knowledge of viral target proteins. Furthermore, the insertion of foreign peptides 
into the capsid structure may interfere with the stability of the viral particle or with the 
infectious process and by incorporation into the viral capsid, peptide ligands might be 
displayed in a non-functional conformation [1],[7]. A more basic restriction of this approach is 
the limited knowledge about cell-type-specific receptors and their natural ligands on clinically 
relevant tissues. The recent development of AAV peptide display libraries allows the 
selection of capsid mutants on various cell types [95],[96] (Figure 5). Two AAV peptide 
libraries have been developed consisting of mutants carrying 7-mer peptides with random 
sequence at amino acid position 587 [95] or 588 [96]. Perabo and colleagues performed five 
selection rounds with an AAV peptide library on MO7e, a megakaryocytic cell line, and on 
Mec1, which is derived from B-cell chronic lymphocytic leukemia (B-CLL) [95]. Both cell 
types are non-permissive for wtAAV2. In two separate selections, RGD-containing peptides 
(RGDAVGV and RGDTPTS) were obtained from the MO7e selections, whereas two different 
peptides were selected on Mec1 (GENQARS and RSNAVVP). rAAV vectors displaying the 
selected peptides on the capsid surface transduced their respective target cells with an up to 
100-fold increased efficiency compared to wtAAV2, and ligand-mediated cell transduction 
was proven by peptide competition. Moreover, one of the mutants selected on Mec1 was 
able to transduce primary B-CLL cells (up to 54%) which are refractory to AAV2 infection. 
Müller and colleagues applied a similar approach for the selection of peptides able to 
mediate the transduction of human coronary artery endothelial cells [96]. Most of the 




selected peptides fitted into the consensus sequence NSVRDLG/S and NSVSSXS/A and 
displayed remarkably higher transduction levels than AAV2 with unmodified capsid on the 
target cells. Furthermore, one of the peptides (NSSRDLG) enabled heart transduction after 
systemic application in mice, whereas only a weak transduction was observed with wtAAV2. 
Depending on the applied selection pressure and the use of viral progeny for further 
selection rounds, the AAV peptide display technology allows the selection of capsid mutants 
that own the characteristics of cell-type-specific cell entry and successful intracellular 




Figure 5: AAV peptide display 
The picture schematically represents the construction of the library of AAV2 capsid-modified particles 
and the selection protocol for the isolation of targeted mutants. A pool of oligonucleotides with random 
sequence has been cloned into an AAV2-genome-encoding plasmid at the site corresponding to 
amino acid 587 of VP1. Following the standard AAV production protocol, a library of approximately 
4x106 capsid-modified AAV2 clones was generated. For the selection of targeted mutants, target cells 
are co-infected with the pool of AAV2 mutants and adenovirus is applied to induce progeny 
production. Fourty-eight hours later, viral progeny is collected and used for the next selection round. 
Figure kindly provided by Luca Perabo © 2003 
 
 
1.2 AAV and its infectious biology 
As briefly mentioned above, rAAV vectors are based on AAV, which is classed into the family 
of Parvoviridae. This family is divided in two subfamilies: Parvovirinae, which infect 
vertebrates, and Densovirinae, which infect insects. Parvovirinae consist of the genera 
Parvoviruses, Amdoviruses, Bocaviruses, Erythroviruses and Dependoviruses, the latter of 
which AAV belongs to. As implicated by its name, AAV often occurs in association with other 




productive infection [7]. To date, 14 serotypes and multiple variants have been described, 
which were isolated either as contaminants of adenoviral preparations or from integrated 
proviral sequences found in rodents, non-human primates and human tissues [104-114]. 
All AAV serotypes contain a single-stranded DNA genome of approximately 5kb, which is 
packaged into an icosahedral, non-enveloped capsid and can be divided into three functional 
regions (Figure 6): two open reading frames (ORF; rep and cap) and the inverted terminal 
repeats (ITR) [115]. The ITRs at the 5’- and 3’-end of the AAV genome serve as origin of 
replication and play a key role in viral genome integration into the host genome as well as in 
the subsequent rescue of viral DNA from the integrated state [116-120]. The rep ORF codes 
for a family of multifunctional nonstructural proteins (Rep) that are involved in viral/vector 
genome replication, transcriptional control, integration and encapsidation of AAV genomes 
into preformed capsids [121-125]. The cap ORF codes for the three capsid proteins VP1, 
VP2 and VP3 [5],[126]. All capsid proteins share a common C-terminus, but differ in their N-
terminus resulting in molecular weights of 90kDa (VP1), 72kDa (VP2) and 60kDa (VP3). 
Considering the functions of the capsid proteins, VP1 is essential for infectivity, whereas VP3 
is sufficient for capsid formation [90]. VP2 is proposed to be neither necessary for capsid 
formation nor for production of infectious particles [90],[91].  
 
 
Figure 6: Capsid and genome structure of AAV2 
A: The picture represents a surface rendering of the AAV2 capsid based on atomic coordinates. The 
colours are depth cued along a colour gradient: yellow at a larger radius, and greenish blue as the 
radius decreases. The view is down the two-fold axis (centre of the virus) with three-folds left and right 
of centre, five-folds above and below. Capsid model kindly provided by Jorge Boucas © 2008 
B: The AAV genome contains of 4680 nucleotides (nts) divided into 100 map units (46.8 nts per unit). 
The AAV genome is flanked by inverted terminal repeats (ITRs), three viral promoters are positioned 
at units 5, 19 and 40 (p5, p19, p40) and the polyadenylation signal (polyA) at unit position 96. Open 
reading frames are shown as cylinders, untranslated regions as solid lines and introns as kinks. p5 





promoter controls the expression of the three different capsid proteins VP1, VP2 and VP3. Scheme of 
AAV genome organization kindly provided by Nadja Huttner © 2003 
 
 
Like in every viral infection, AAV has to subsequently overcome numerous barriers – namely 
receptor binding, cell entry, intracellular trafficking, endosomal release, viral uncoating and 
nuclear entry – before it can deliver its genome into the nucleus for replication. The current 
knowledge of the AAV infectious biology is limited and the most detailed information is 
available for AAV serotype 2 (AAV2) (Figure 7). Single virus tracing technology revealed that 
AAV2 virions usually contact the cell membrane multiple times before internalization 
succeeds [127]. This characteristic most likely reflects the interaction of the capsids with 
HSPG, the primary receptor for AAV2 [6]. Also AAV3 is suggested to use HSPG as primary 
receptor, whereas the serotypes 1, 4, 5 and 6 bind to sialic acid [128],[129],[12]. N-linked 
sialic acids were identified as a primary receptor for AAV1, AAV5 and AAV6, while AAV4 
binds to O-linked sialic acids. PDGFR was recently identified as a receptor for AAV5, and 
AAV8 was shown to bind to the laminin receptor (LamR) [130],[13]. LamR was also proposed 
to be involved in AAV2-, AAV3- and AAV9-mediated cell infection [130]. 
As mentioned in paragraph 1.1, AAV2 enters the cell in a two-step mechanism. Binding of 
AAV2 to its primary receptor HSPG is likely to induce a reversible structural rearrangement 
of the capsid required for the next step in viral entry, which is dependent on co-receptors 
[31]. The co-receptors FGFR-1, HGFR and laminin receptor may enhance the virus-cell 
contact, thereby facilitating the HSPG-induced structural rearrangement of the capsid [7], 
whereas integrins (αvβ5, α5β1) are thought to mediate endocytosis of AAV2 [9],[131]. Integrin 
binding subsequently leads to the activation of the small GTPase Rac1 and 
phosphatidylinositol-3 kinase (PI3K) which results in cytoskeletal rearrangements that 
promote clathrin-dependent internalization of AAV2 as well as trafficking of AAV2 from the 
cell periphery towards the nucleus [9],[10],[132-134]. AAVs – at least serotype 5 – do not 
exclusively use clathrin-coated pits to enter the cell. Specifically, AAV5 is able to exploit both 
the clathrin-mediated pathway and caveolin-dependent internalization [14],[15].  
Once internalized, AAV is trafficked mainly inside endosomes. Organelle separations, 
inhibitor and imaging studies revealed the presence of AAV2 particles in endosomal 
compartments [11],[127],[135-138]. These virus-containing vesicles were further shown to be 
transported along microfilaments and microtubules [9],[11],[136]. When and how AAV 
escapes from the endosome is still a matter of debate and may be cell type specific. For 
AAV2, evidence for viral release from early endosomes [11],[138], late endosomes 
[135],[136] or even perinuclear recycling endosomes [135] has been provided. In addition, 
AAV2 and AAV5 have been detected in the trans-Golgi network [14],[15],[137]. As described 




[11],[136],[137] and believed to trigger conformational changes of the viral capsid leading to 
exposure of previously hidden regions, which mediate endosomal escape and nuclear entry 
[140]. The N-terminus of VP1 contains a phospholipase A2 (PLA2) homology domain that is 
conserved among parvoviruses and becomes exposed during the AAV infection process 
[141],[142]. PLA2 exhibits the catalytic activity of hydrolysing phospholipids into free fatty 
acids and lysophospholipids, which is thought to mediate endosomal escape of parvoviruses, 
including AAV2, by lipolytic pore formation [142],[143],[Stahnke et al., in revision]. 
When released from the endosome, the AAV capsid may be a target for ubiquitination and 
subsequent proteasomal degradation [144],[145]. Likewise, proteasome inhibitors enhanced 
cell transduction mediated by AAV1 to AAV5, AAV7 and AAV8 [136],[146-149]. In addition to 
inhibiting AAV degradation, proteasome inhibitors may affect viral genome translocation into 
or accumulation within the nucleus [150]. 
Viral particles start to accumulate in the perinuclear area between 15 and 30min post 
infection (p.i.) [11],[91],[127]. The majority of these virions still have intact viral capsids filled 
with viral genomes [91]. Furthermore, accumulation of viral particles in nuclear invaginations 
has been observed [91]. The question if viral uncoating happens before or after nuclear entry 
is still not answered. Several groups have described intact AAV particles in the nucleus, but 
data regarding the mechanism and efficiency of capsid import as well as their role in viral 
infection are controversial [9],[11],[91],[138],[151],[152]. However, Lux and colleagues 
revealed that nuclear entry of viral capsids is a rare event and that uncoating occurs before 
or during entry into the nucleus: at virus to cell ratios, at which viral genomes could be 
detected within the nucleus, signals of intact viral capsids were exclusively detected outside 
the nucleus [91]. Moreover, it is still a matter of debate whether AAV and/or AAV genomes 
enter the nucleus through the nuclear pore complex (NPC) or in a NPC-independent way 
[140],[152],[153].  
Within the nucleus, the single-stranded AAV genome is converted into a transcriptionally 
active, double-stranded form. This genome conversion was shown to be a rate-limiting step 
in AAV infection, which is facilitated by adenoviral genes [154],[155]. Dependent on the 
presence or absence of a helper virus, AAV enters a lytic or latent life cycle.  In the absence 
of helper functions, AAV enters a latent cycle and integrates at a specific locus known as 
AAVS1 on chromosome 19 (19q13.3-qter) [156],[157]. Prior to viral integration, second- 
strand synthesis and basal expression of the Rep proteins is activated [158],[159]. Rep 
proteins bind the viral genome at a Rep binding site located in the viral ITRs, and a 
homologous sequence in the AAVS1 locus, and mediate integration [160-162]. Integrated 
proviruses can be rescued by superinfection with a helper virus [163]. In the presence of a 







Figure 7: Current model of AAV2 infection in HeLa cells 
AAV2 makes repeated contacts with the cell by binding to its negatively charged primary receptor 
heparan sulphate proteoglycan (HSPG) mediated by a cluster of basic amino acids in the AAV2 
capsid. The attachment is enhanced by FGFR and/or HGFR binding. Subsequent binding to integrins 
leads to endocytosis via clathrin-coated pits. Integrin binding is assumed to activate the small GTP 
binding protein Rac1, which stimulates the PI3K pathway. The resulting rearrangement of the 
cytoskeleton allows trafficking of AAV2-containing endosomes. Acidification of the endosome may 
lead to conformational changes in the AAV2 capsid and its release. Uncoating and release of the viral 
genome takes place before or during nuclear entry. After transport of the AAV2 genome into the 
nucleus, the genome is replicated, integrated into the host genome or stays episomally. NPC: nuclear 





1.3 Aim of the study 
AAV targeting technologies hold promise to overcoming two major drawbacks in viral gene 
delivery, namely transduction of AAV-refractory cell types and avoidance of non-target cell 
transduction. Ligand-mediated cell transduction by AAV targeting vectors can achieve both 
re-targeting to target cells of interest and de-targeting from the natural tropism depending of 
the inserted peptide. Besides the fact that capsid modification leads to a change of viral 
tropism, to date, little is known about consequences of peptide insertions on the virus-host 
interplay. However, to optimize efficiency and safety of AAV targeting vectors, a detailed 
understanding of the vector-cell interaction is pivotal. Since the peptide ligands inserted into 
the viral capsid mediate target cell transduction, differences in the intracellular processing of 
the targeting vectors in comparison to non-targeted, unmodified AAV vectors are anticipated.  
This work aimed to clarify, how targeting non-natural receptors by the insertion of peptides 
into the AAV capsid influences the vector-cell interplay. Knowing that peptide insertions at 
amino acid position 587 in the AAV capsid can either disrupt, conserve or restore the ability 
to bind to HSPG which determines the in vivo tropism of AAV targeting vectors [103], HSPG-
binder and HSPG-non-binder mutants ought to be selected by AAV peptide display. The 
generated AAV peptide insertion mutants should serve as tools for the analysis of cell entry 
and intracellular processes like proteasomal degradation and transgene expression in 
comparison to unmodified rAAV2. To elucidate distinct steps of the vector-cell interaction, 
different techniques were to be applied, e.g. inhibitor studies to analyze the cell entry 
mechanism, qPCR to quantify uptake and transcription of vector genomes and subcellular 
fractionation to monitor the intracellular distribution of vector particles. With these means, this 
study should lead to an improvement in the basic knowledge of cell transduction by AAV 
peptide insertion mutants, which is necessary for their use in targeted gene delivery in vivo.  
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2.1.1 Chemicals, solutions and enzymes 
Product Company 
4′,6-Diamidino-2-phenylindol (DAPI) Sigma-Aldrich, Taufkirchen, Germany 
Agar-Agar Roth, Karlsruhe, Germany 
Agarose Invitrogen, Karlsruhe, Germany 
Ammonium Chloride Merck, Darmstadt, Germany 
Ampicillin Sigma-Aldrich, Taufkirchen, Germany 
APS Invitrogen, Karlsruhe, Germany 
Aqua bidest. (Ampuwa) Fresenius Kabi, Homburg, Germany 
Bafilomycin Sigma-Aldrich, Taufkirchen, Germany 
Bovine Serum Albumine AppliChem, Darmstadt, Germany 
Calcium Chloride Sigma-Aldrich, Taufkirchen, Germany 
Chlorpromazine Sigma-Aldrich, Taufkirchen, Germany 
Dimethyl sulfoxide (DMSO) Riedel-de Haën, Seelze, Germany 
DNA restriction endonucleases MBI Fermentas, St. Leon-Rot, Germany; 
New England Biolabs, Frankfurt, Germany 
DMEM Medium + GlutaMAXTM-I Invitrogen, Karlsruhe, Germany 
EDTA Roth, Karlsruhe, Germany 
Ethanol Roth, Karlsruhe, Germany 
Ethidium Bromide Roth, Karlsruhe, Germany 
Gelatine Sigma-Aldrich, Taufkirchen, Germany 
Genistein Sigma-Aldrich, Taufkirchen, Germany 
Glycerol Roth, Karlsruhe, Germany 
Heparin B. Braun Melsungen AG, Germany 
HEPES Roth, Karlsruhe, Germany 
Iodixanol Sigma-Aldrich, Taufkirchen, Germany 
Isopropanol Roth, Karlsruhe, Germany 
Magnesium Chloride Roth, Karlsruhe, Germany 
MassRuler DNA Ladder Mix MBI Fermentas, St. Leon-Rot, Germany 
MG-132 Sigma-Aldrich, Taufkirchen, Germany 
NP-40 Sigma-Aldrich, Taufkirchen, Germany 
PBS Invitrogen, Karlsruhe, Germany 
Penicillin/Streptomycin Invitrogen, Karlsruhe, Germany 
Peptone/Tryptone Roth, Karlsruhe, Germany 
PIPES Sigma-Aldrich, Taufkirchen, Germany 
PhusionTM DNA Polymerase  Finnzymes, Keilaranta, Finland 
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RPMI-1640 medium + GlutaMAXTM-I Invitrogen, Karlsruhe, Germany 
Precision Plus Protein Gel Color Standards Bio-Rad Laboratories GmbH, München, 
Germany 
Sodium Dodecyl Sulfate (SDS) Merck, Darmstadt, Germany 
Sodium Phosphate Roth, Karlsruhe, Germany 
Streptavidin peroxidase conjugate Dianova, Hamburg, Germany 
T4 DNA Ligase MBI Fermentas, St. Leon-Rot, Germany 
TEMED Sigma-Aldrich, Taufkirchen, Germany 
TMB Sigma-Aldrich, Taufkirchen, Germany 
Transferrin from human serum, Alexa Fluor® 
488 conjugate 
Invitrogen Molecular Probes, Karlsruhe, 
Germany 
Tris Merck, Darmstadt, Germany 
Triton X 100 Sigma-Aldrich, Taufkirchen, Germany 
Trypsin-EDTA Invitrogen, Karlsruhe, Germany 
Tween 20 Merck, Darmstadt, Germany 
Vectashield VC-H-1400 Vector Laboratories, Inc., Burlingame, USA 
Western LightningTM Chemiluminescence 
Reagent Plus 
PerkinElmer Life Sciences, Boston, USA 
 
All other chemicals were bought from Sigma-Aldrich (Taufkirchen, Germany), Merck 
(Darmstadt, Germany) or Carl Roth GmbH & Co. (Karlsruhe, Germany). 
 
2.1.2 Standard kits 
Product Company 
BigDye® Terminator v3.1 Cycle Sequencing Kit Applied Biosystems, Foster City, USA 
DNeasy® Blood & Tissue Kit Qiagen, Hilden, Germany 
EndoFree® Plasmid Kits Qiagen, Hilden, Germany 
Gel Extraction Kit Qiagen, Hilden, Germany 
LightCycler® 480 SYBR Green Master Roche, Mannheim, Germany 
LightCycler® FastStart DNA Master SYBR 
Green I 
Roche, Mannheim, Germany 
RNase-free DNase Set Qiagen, Hilden, Germany 
RNeasy® Tissue Kit Qiagen, Hilden, Germany 
PCR Purification Kit Qiagen, Hilden, Germany 
Qproteome Cell Compartment Kit Qiagen, Hilden, Germany 
SuperScriptTM III First-Strand Synthesis 
SuperMix for qRT-PCR 
Invitrogen, Karlsruhe, Germany 
 
2.1.3 Plasmids 
peGFP-VP2.2: Plasmid encoding a fusion protein of eGFP and AAV2 VP2; Kanamycin-
resistance; plasmid kindly provided by K. Lux 
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peGFP-VP2.2-“XN587”: Plasmid encoding a fusion protein of eGFP and AAV2 VP2 carrying 
a targeting insertion at position 587. “XN587” represents the targeting insertion A2 
(ASASNSVRSDAA), B1 (ASANGIRRFDAA), C2 (ASANGIRSFDAA) or D5 
(ASAKGTKAPKAA). Kanamycin-resistance; plasmids were generated in this PhD work. 
pGFP: EGFP cDNA controlled by the human cytomegalovirus (CMV) promoter and 
hygromycin resistance gene controlled by the thimidine kinase promoter flanked by the AAV2 
ITRs; Ampicillin-resistance [164] 
pLuci: Luciferase gene controlled by the CMV promoter, flanked by one intact ITR and one 
ITR containing a mutated terminal resolution site. The plasmid is packaged as pseudo-
double-stranded genome. Ampicillin-resistance; plasmid kindly provided by S. Quadt-Humme 
pmCherry-VP2.2: Plasmid encoding a fusion protein of mCherry and AAV2 VP2; 
Kanamycin-resistance; plasmid kindly provided by S. Stahnke 
pRC: AAV based helper plasmid containing the AAV2 Rep and Cap open reading frame 
(ORF) but lacking the viral ITRs; Ampicillin-resistance [86] 
pRC99: AAV based helper plasmid containing the AAV2 Rep and Cap ORF but lacking the 
viral ITRs, containing MluI and AscI cloning sites flanking the amino acid position 587; 
Ampicillin-resistance [93] 
pRC99-“XN587”: AAV based helper plasmid containing the AAV2 Rep and Cap ORF 
carrying a targeting insertion at position 587 but lacking the viral ITRs. Ampicillin-resistance; 
plasmids were generated in this PhD work. 
pRC”Kotin”: AAV based helper plasmid containing the AAV2 Rep and Cap ORF but lacking 
the viral ITRs, containing SnaBI and BsiWI cloning sites within the Cap ORF; Ampicillin-
resistance; plasmid kindly provided by A. Girod 
pRC VP2 k.o.: Plasmid encoding Rep-Proteins and capsid proteins VP1 and VP3. Ampicillin-
resistance; plasmid kindly provided by K. Lux 
pRC VP2 k.o.-“XN587”: Plasmid encoding Rep-Proteins and capsid proteins VP1 and VP3 
carrying a targeting insertion at position 587. Ampicillin-resistance; plasmids were generated 
in this PhD work. 
pRGD-4C-587: AAV based helper plasmid containing the AAV2 Rep and Cap ORF like pRC; 
the RGD4C peptide – ACDCRGDCFCA – is inserted at position N587; Ampicillin-resistance 
[87] 
pXX6-80: Adenoviral helper plasmid encoding for VA, E2A and E4, kindly provided by J. 
Samulski (University of North Carolina, Chapel Hill, USA); Ampicillin-resistance [165]  





All primers have been purchased from Invitrogen (Karlsruhe, Germany). 
 
Sequencing primer 
4066_rev  5’ – ATGTCCGTCCGTGTGTGG – 3’ 
 
Primers for qPCR  
AlasI_fw  5’ – CAATCAATTACCCTACGGTG – 3’ 
AlasI_rev  5’ – CAAAATGCAGTGGCCT – 3’ 
GFP_fw  5’ – GCTACCCCGACCACATGAAG – 3’ 
GFP_rev  5’ – GCTCATGCCGAGAGTGATCC – 3’ 
Luci_fw  5’ – CGTGCTGGACTCCTTCATCA – 3’ 
Luci_rev  5’ – TTGCGGACAATCTGGACGAC – 3’ 
Plat_fw  5’ – ACCTAGACTGGATTCGTG – 3’ 
Plat_rev  5’ – AGAGGCTAGTGTGCAT – 3’ 
wt_fw   5’ – GGTACGACGACGATTGCC – 3’ 
wt_rev   5’ – ATGTCCGTCCGTGTGTGG – 3’ 
 
Primers for amplification of selected clones 
BsiWI_fw  5’ – TACCAGCTCCCGTACGTCCTCGGC – 3’ 
NewSnaBI_rev 5’ – CGCCATGCTACTTATCTACG – 3’ 
 
2.1.5 Single-stranded oligonucleotides 
All single-stranded oligonucleotides were 5’-phosphorylated and purchased from Metabion 
(Martinsried, Germany). 
 
A2_sense:  5’ – C GCG TCC GCG TCT AAC TCG GTG CGA TCG GAC GCG G – 3’ 
A2_antisense: 5’ – CG CGC CGC GTC CGA TCG CAC CGA GTT AGA CGC GGA – 3’ 
B1_sense:  5’ – C GCG TCC GCG AAC GGG ATC CGG AGG TTT GAC GCG G – 3’ 
B1_antisense: 5’ – CG CGC CGC GTC AAA CCT CCG GAT CCC GTT CGC GGA – 3’ 
C2_sense:  5’ – C GCG TCC GCG AAC GGG ATC CGG AGC TTC GAC GCG G – 3’ 
C2_antisense: 5’ – CG CGC CGC GTC GAA GCT CCG GAT CCC GTT CGC GGA – 3’ 
D5_sense:  5’ – C GCG TCC GCG AAG GGC ACC AAG GCG CCC AAG GCG G – 3’ 
D5_antisense: 5’ – CG CGC CGC CTT GGG CGC CTT GGT GCC CTT CGC GGA – 3’ 
 





2.1.6.1   Primary antibodies 
name antigen generated in clonality manufacturer 
A20 AAV intact capsid mouse polyclonal hybridoma supernatant kindly 
provided by J. Kleinschmidt, 
DKFZ Heidelberg, Germany 
anti-AKT AKT rabbit polyclonal Cell Signaling Technologies 
Inc., Danvers, USA 
anti-Lamin B Lamin B goat polyclonal Santa Cruz Biotechnology 
Inc., Santa Cruz, USA 
anti-Rab5 Rab5 mouse monoclonal Santa Cruz Biotechnology 
Inc., Santa Cruz, USA 
B1 C-terminus of VP1, 
VP2, VP3 
mouse monoclonal hybridoma supernatant kindly 
provided by J. Kleinschmidt, 
DKFZ Heidelberg, Germany 
 
2.1.6.2 Secondary antibodies 
Donkey anti-goat IgG-HRP (Santa Cruz Biotechnology Inc., Santa Cruz, USA) 
Donkey anti-mouse IgG-HRP (Jackson ImmunoResearch Ltd., Suffolk, UK) 
Donkey anti-rabbit IgG-HRP (Jackson ImmunoResearch Ltd., Suffolk, UK) 
Donkey anti-goat Cy5 (Dianova, Hamburg, Germany) 
Rabbit anti-mouse IgG-biotin (Dianova, Hamburg, Germany) 
 
2.1.7 Bacteria strain 
Escherichia coli: 
For chemical transformation, the E. coli strain DH5α was used.  
Genotype: F-, lac1-, recA1, endA1, hsdR17, (lacZYA-argF), U169, F80dlacZ_M15, supE44, 
thi-1, gyrA96, relA1 [166] 
 
2.1.8 Eukaryotic cell lines 
BLM: Human melanoma cells; kindly provided by C. Mauch, Cologne 
HEK293: Human embryonic kidney cells, transformed with Ad5 DNA and containing the 
adenoviral genes E1a and E1b, American Type Culture Collection (ATCC) CRL-1573 [167] 
HeLa: Human epithelial cervix adenocarcinoma cells; ATCC CCL-2 [168] 
HepG2: Human epithelial hepatocellular carcinoma cells; ATCC HB-8065 [169]  
K-562: Human chronic myelogenous leukemia cells; ATCC CCL-243 [170] 




2.1.9 Laboratory equipment and disposables 
Product Company 
Balance Adventurer Pro Ohaus, NJ, USA 
Biomax Light Film  Kodak, Stuttgart, Germany 
Capillary Light Cycler Roche, Mannheim, Germany 
Cell Culture Plastic Ware TPP AG, Trasadingen, Switzerland 
Centrifuge Z 216 MK Hermle, Wehingen, Germany 
Centrifuge Z 233 M-2 Hermle, Wehingen, Germany 
Centrifuge Z 383 K Hermle, Wehingen, Germany 
Centrifuge 5415 D Eppendorf, Hamburg, Germany 
Cell scrapers Corning Incorporated 
CO2 Incubator MCO-20AIC Sanyo, München, Germany 
Cover slips 10mm Roth, Karlsruhe, Germany 
FACS Calibur  Becton Dickinson, Heidelberg, Germany 
FACS tubes Becton Dickinson, Heidelberg, Germany 
General laboratory ware  VWR, Darmstadt, Germany 
Heater/Magnetic stirrer Heidolph MR 3001 Heidolph Instruments, Schwabach, Germany 
Hera -80ºC freezer  Heraeus/Thermo Fisher Scientific, Germany 
HiTrap Heparin Affinity Columns (1ml)  Amersham /GE Healthcare, Freiburg, 
Germany 
Incubator Shaker Multitron Standard Infors HT, Bottmingen-Basel, Switzerland 
Laminar Air Flow BioWizard Golden Line  Kojair, Vilppula, Finland 
Laminar Air Flow BioWizard Xtra Kojair, Vilppula, Finland 
LightCycler 480 II Roche, Mannheim, Germany 
Light Cycler plates and foils Roche, Mannheim, Germany 
LightCycler Capillaries  Roche, Mannheim, Germany 
LightCycler carousel centrifuge  Roche, Mannheim, Germany 
Microscope Olympus CKX41 Olympus, Hamburg, Germany 
Mini Sub GT Gel Electrophoresis Unit  BioRad, München, Germany 
Mini Trans-Blot Electrophoretic Transfer Cell BioRad, München, Germany 
Nitrocellulose membrane (Hybond ECL) Amersham/GE Healthcare, Freiburg, 
Germany 
Parafilm  Pechinery Plastic Packaging, Chicago, USA 
Pharmacia GeneQuant spectrophotometer Pharmacia/GE Healthcare, Freiburg, 
Germany 
pH Meter Seven Easy  Mettler-Toledo, Schwerzenbach, Switzerland 
Pipettes and Filtertips  Sarstedt, Nümbrecht, Germany 
Power Supply  Renner, Dannstadt, Germany 
Pump P-1  Amersham/GE Healthcare, Freiburg, 
Germany 
Reaction tubes (1.5ml, 2ml)  Eppendorf, Hamburg, Germany 
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Reaction tubes (15ml, 50ml) Sarstedt, Nümbrecht, Germany; 
Becton Dickinson, Heidelberg, Germany 
Scalpels Feather Safety Razor Co. Ltd., Japan 
Sorvall T-865 rotor  Thermo Fisher Scientific, Germany 
Sorvall Ultracentrifuge OTD Combi  Thermo Fisher Scientific, Germany 
Syringes and Needles  B. Braun Melsungen, Melsungen, Germany 
Thermomixer Comfort  Eppendorf, Hamburg, Germany 
Ultracentrifuge tubes Kendro/Thermo Fisher Scientific, Germany 
Vortex Genie 2  Scientific Industries, NY, USA 
Waterbath Medingen W6  Medingen, Freital, Germany 
Whatman filter paper Schleicher&Schuell, Dassel, Germany 
 
2.1.10 Data treating software 
Adobe Photoshop CS4, Chromas Lite, Clone Manager, IrfanView, LightCycler 480 Software 
1.5, Microsoft Excel, RelQuant, WinMDI, Zotero, specific software for the respective 
instruments 





2.2.1 Bacteria culture 
2.2.1.1 Cultivation of bacteria 
Bacteria were grown in LB medium at 37°C over night while vigorously shaking. For growing 
bacteria on plates, 15g/l Agar was added to LB medium for solidification. For transformed 
bacteria with resistance to Ampicillin or Kanamycin, 100mg/l Ampicillin or 50mg/l Kanamycin 
was added to the medium. 
 
LB medium:  10g Peptone/Tryptone 
5g Yeast extract 
10g NaCl 
15g agar (for plates) 
ad 1l distilled H2O 
 
2.2.1.2 Preparation of chemically competent bacteria 
The bacteria strain DH5α was grown at 37°C on vigorous shaking (200rpm) over night in 8 ml 
of LB medium. Ten hours later, 4ml of this culture were transferred into 400ml of LB medium 
and bacteria were grown to an optical density (OD590) of 0.4. Cultured bacteria were divided 
in two parts and incubated on ice for 10min followed by centrifugation at 1600xg for 7 min at 
4°C. Each pellet was carefully resuspended in 40ml ice-cold sterilized CaCl2 solution 
followed by centrifugation at 1100xg for 5min at 4°C. Pellets were resuspended as described 
before and incubated on ice for 30min followed by centrifugation at 1100xg for 5min at 4°C. 
Each pellet was carefully resuspended in 8ml ice-cold CaCl2 solution. After pooling the two 
parts, 100µl aliquots of the chemically competent bacteria were immediately shock-frozen in 
liquid N2 and stored at –80°C. 
 
CaCl2 solution:  60mM CaCl2  
10mM PIPES (pH 7.0) 
15% Glycerol (v/v) 
 
2.2.1.3 Transformation of bacteria 
Competent bacteria were slowly thawn on ice. After adding 100µl of competent bacteria to 
the transforming DNA (100–500ng) carrying Ampicillin or Kanamycin resistance, the 
suspension was mixed and incubated on ice for 30min. Then, the suspension was incubated 
for 45sec at 42ºC followed by an incubation on ice for 2min.  One ml of LB medium was 
added and the mixture shaken at 200rpm and 37ºC for 30-60min. Bacteria were distributed 
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on LB agar plates already containing Ampicillin (100µg/ml) or Kanamycin (50µg/ml). Plates 
were incubated over night at 37ºC. The next day, a single colony was picked from the plate, 
grown as described before and analyzed. 
 
2.2.2 Working with nucleic acids 
2.2.2.1 Plasmid amplification and extraction 
For plasmid amplification and extraction, the Qiagen EndoFree Plasmid Mega Kit was used 
according to the manufacturer’s instructions. 
 
2.2.2.2 DNA and RNA quantification 
DNA and RNA samples were diluted in H2O before they were measured in a Pharmacia 
GeneQuant spectrophotometer. Samples were measured at a wavelength of 260nm and 
280nm. Purity of the nucleic acid preparation is given by the ratio Abs 260nm / Abs 280nm. 
DNA of high purity has a ratio of 1.8, lower values point to contaminations with proteins and 
aromatic substances, whereas higher ratios indicate possible contaminations with RNA.  
 
2.2.2.3 Restriction enzyme digest 
Digestion with restriction enzymes was performed according to the manufacturer’s 
instructions in a final volume of 20µl containing 1µg of DNA, 1-10 units of restriction enzyme 
per 1µg DNA and 1x buffer. 
 
2.2.2.4 Agarose gel electrophoresis and gel extraction 
Restriction enzyme digests as well as PCR products were analyzed by agarose gel 
electrophoresis to verify the size of the fragments or PCR products. 
1x TBE buffer was boiled with the desired amount of agarose (0.7% to 2%, depending on 
fragment size) and mixed with the DNA intercalating substance ethidium bromide (0.1µg per 
1ml gel volume). Electrophoresis was performed at 80V and 200mA in 1x TBE buffer. 
 
TBE Buffer (10x):  540g Tris base 
275g boric acid 
200ml 0.5M EDTA pH 8.0 
ad 5l H2O 
 
Extraction of DNA fragments or PCR products from agarose gels was performed using the 
Qiagen Gel Extraction Kit according to the manufacturer’s instructions. 




2.2.2.5 DNA extraction from animal cells 
DNA was extracted from animal cells using the Qiagen DNeasy Blood & Tissue Kit following 
the protocol for “Purification of Total DNA from Animal Blood or Cells” according to the 
manufacturer’s instructions and eluted in 100µl 10mM Tris/HCl pH 8.5. 
 
2.2.2.6 RNA extraction from animal cells and DNase I digest 
RNA was extracted from animal cells using the Qiagen RNeasy Mini Kit following the 
protocol for “Purification of Total RNA from Animal Cells” according to the manufacturer’s 
instructions and eluted in 30µl sterile H2O.  
The “On-column DNase Digestion with the RNase-free DNase Set” (Qiagen) was included in 
the RNA extraction protocol according to the manufacturer’s instructions. 
 
2.2.2.7 cDNA synthesis 
cDNA synthesis from 8µl total RNA (2.2.2.6) was performed using the SuperScriptTM III First-
Strand Synthesis SuperMix for qRT-PCR (Invitrogen) according to the manufacturer’s 
instructions. 
 
2.2.2.8 Polymerase chain reaction (PCR) 
Viral DNA obtained after the third selection round (2.2.6.2) was amplified for subsequent 
cloning into the AAV helper plasmid pRC”Kotin”. Using the primers BsiWI_fw and 
NewSnaBI_rev and the below described reaction conditions, a 1.2kb fragment surrounding 
the targeting insertion at amino acid position 587 (corresponding to nucleotides 6018-6020 in 
the Cap ORF) from nt 5311 to nt 6532 was amplified. 
 
PCR reaction mix:  
5µl template DNA 
2µl dNTPs (10mM) 
10µl 5xPhusion reaction buffer 
2µl BsiWI_fw (10µM) 
2µl New SnaBI_rev (10µM) 
0.5µl PhusionTM DNA Polymerase 
ad 50µl H2O 
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PCR cycling program: 
Denaturation 30 sec 98°C 
Denaturation 10 sec 98°C  
Annealing 30 sec 56°C         35x 
Elongation 40 sec 72°C 
Final elongation 10 min 72°C 
Final hold hold 4°C 
 
 
2.2.2.9 Quantitative PCR (qPCR) 
Quantitative PCR was performed to determine either the genomic titer of rAAV vector stocks 
(absolute quantification) or the amount of DNA or cDNA in a sample (relative quantification of 
target versus reference gene). In case of absolute quantification, absolute standards were 
included in the qPCR reaction. For relative quantification, a calibrator standard curve was 
generated for normalization of target versus reference value. For reasons of accuracy, the 
calibrator standard curve was prepared by serial dilution (1:5, 1:10, 1:50, 1:100) of the 
sample with the highest expected amount of target gene. Relative quantification was carried 
out using the RelQuant software for Capillary LightCycler or the LightCycler® 480 Software 
1.5 for LightCycler® 480 II. 
The Light Cycler System (LightCycler® 480 II or Capillary LightCycler, both from Roche) and 
the appropriate kit (LightCycler® 480 SYBR Green Master for LightCycler® 480 II, 
LightCycler® FastStart DNA Master SYBR Green I for Capillary LightCycler) was chosen 
depending on amount of samples and type of analysis. 
2µl of DNA or cDNA was put per reaction. For determination of genomic titer of AAV vector 
preparations, 2µl of the extracted DNA was analyzed. 
 
Pipetting scheme using LightCycler® Fast Start DNA Master SYBR Green I: 
2µl template DNA 
1µl Primer fw (20µM) 
1µl Primer rev (20µM) 
4µl Mix (including FastStart Taq DNA Polymerase, reaction buffer, dNTP mix, SYBR   
Green I dye and MgCl2) 
ad 20µl H2O 
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Pipetting scheme using LightCycler® 480 SYBR Green Master: 
2µl template DNA 
1µl Primer fw (20µM) 
1µl Primer rev (20µM) 
10µl Mix (including FastStart Taq DNA Polymerase, reaction buffer, dNTP mix, SYBR   
Green I dye and MgCl2) 
ad 20µl H2O 
 
Using the below-mentioned qPCR cycling program, genomic titers were determined for rAAV 
vector preparations carrying either GFP or Luciferase as transgene. The same program was 
used to analyze transduced cells with regard to vector DNA or vector transcripts (GFP), the 
single-copy gene Plat (exon priming on genomic DNA) and the single-copy transcript AlasI 
(exon priming on cDNA). Specificity of PCR products was assured by melting peak analysis. 
qPCR cycling program: 












Denaturation 1 None 95 None 00:05:00 4.4  
Amplification 40 Quantification 95 None 00:00:15 4.4  
   60 None 00:00:10 2.2  
   72 Single 00:00:20 4.4  
Melting 1 Melting Curve 95 None 00:00:01 4.4  
   68 None 00:00:15 2.2  
   95 Continous   5 
Cooling 1 None 40 None 00:00:30 2.2  
 
Genomic titers of the AAV peptide display library and the progeny of each selection round 
were determined using the wild-type AAV (wtAAV) qPCR cycling program. 
wtAAV qPCR cycling program: 












Denaturation 1 None 95 None 00:15:00 4.4  
Amplification 40 Quantification 95 None 00:00:10 4.4  
   60 None 00:00:03 2.2  
   72 Single 00:00:35 4.4  
Melting 1 Melting Curve 95 None 00:00:01 4.4  
   68 None 00:00:10 2.2  
   95 Continous   5 
Cooling 1 None 40 None 00:00:30 2.2  
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2.2.2.10 Sequencing  
Sequencing of single DNA clones was carried out in an ABI 3730 Sequencer at the Cologne 
Center for Genomics, University of Cologne, Germany. For the sequencing reaction, the 
BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) was used.  
 
Sequencing reaction mix: 
200ng template DNA 
0.5µl 10xBuffer 
0.5µl Primer 4066 (10pmol/µl) 
1µl BigDye v3.1 
ad 5µl H2O 
 
PCR cycling program: 
Denaturation 2 min 94°C 
Denaturation 20 sec 94°C  
Annealing 30 sec 50°C         25x 
Elongation 4 min 60°C 
Final elongation 4 min 60°C 
Final hold hold 4°C 
 
 
2.2.2.11 Molecular Cloning 
2.2.2.11.1 Cloning amplified viral DNA 
100ng of vector backbone (pRC”Kotin” plasmid, digested with SnaBI and BsiWI and 
dephosphorylated) was mixed with a 5-fold excess of insert (purified PCR product (2.2.2.8), 
digested with SnaBI and BsiWI). The amount of insert was calculated using the equation 
weightfragment[ng] = 5 x weightvector[ng] x lengthfragment[bp] / lengthvector[bp]. T4 ligation mix 
containing reaction buffer and 5 Weiss units of T4 DNA Ligase was added. The reaction 
mixture was incubated at 16°C over night and transformed into chemically competent 
bacteria (2.2.1.3). Sequencing of bacterial clones was performed using Primer 4066 (Qiagen 
Sequencing Services, Hilden, Germany) after picking single colonies of the plated cultures. 
 
2.2.2.11.2 Re-cloning viral insertion sequences 
The plasmids pRC99-A2, pRC99-B1, pRC99-C2 and pRC99-D5 were generated by sticky-
end ligation of double-stranded oligonucleotides containing the respective sequences of A2, 
B1, C2 and D5 (2.1.5) into pRC99 vector backbone (previously digested with MluI and AscI 
and dephosphorylated). Briefly, annealing of 50µg sense oligonucleotide and 50µg antisense 
oligonucleotide was performed in 150mM NaCl and 10mM Tris/HCl pH 7.4. Initial heating of 
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the reaction mix for 3min at 95°C was followed by cooling down over night to allow nucleic 
acid hybridization. The resulting double-stranded oligonucleotide displayed 5’ and 3’ sticky 
ends complementary to the cohesive ends of the MluI- and AscI-cut pRC99 backbone. 
Ligation and transformation into chemically competent bacteria was performed as described 
before (2.2.1.3, 2.2.2.11.1). 
 
2.2.2.11.3 Cloning GFP-tagged rAAV peptide insertion mutants 
An 800 bp fragment surrounding the specific peptide insertions of the vectors A2, B1, C2 and 
D5 at amino acid (aa) position 587 (corresponding to nt 6020 in the Cap ORF) from nt 5311 
to 6063 was cut from the pRC99 plasmids using BsiWI and XcmI. The fragments were 
cloned into peGFP-VP2.2 and pRC VP2 k.o. (both previously cut with BsiWI and XcmI and 
dephosphorylated) in order to generate vectors displaying the peptide ligand in the common 
VP3 region of all three capsid proteins and, in addition, having a genetically fused GFP-tag at 
the N-terminus of VP2. Ligation and transformation into chemically competent bacteria was 
performed as described before (2.2.1.3, 2.2.2.11.1). 
 
2.2.3 Working with proteins 
2.2.3.1 Protein extraction from HeLa cells 
1x106 cells – previously washed with 1x PBS and trypsinized – were pelleted at 500xg for 
5min. The supernatant was discarded, the pellet was washed with 1x PBS and centrifuged 
again. As before, the supernatant was discarded, the pellet was resuspeded in 200µl ice-cold 
RIPA buffer and incubated on ice for 30min. Then, the lysate was centrifuged at 16000xg for 
30min at 4°C. The supernatant containing the extracted proteins was transferred to a clean 
tube and stored at –80°C. 
 
RIPA buffer:  0.5% DOC 
0.1% SDS 
150mM NaCl 
50mM Tris pH 8.0 
1% NP-40 
 
2.2.3.2 Acetone precipitation of proteins 
To concentrate and desalt protein samples, four volumes of ice-cold acetone were added to 
the sample followed by 15min incubation on ice and centrifugation at 12000xg for 10min at 
4°C. The supernatant was discarded and the pellet air-dried. Then, the pellet was 
resuspended in 100-200µl 1x PBS and stored at –80°C. 
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2.2.3.3 Western Blot 
Western blot analysis was performed on protein extracts from whole cells or subcellular 
fractions or on iodixanol gradient purified vector preparations.  
Laemmli buffer was added to the samples followed by incubation at 95ºC for 5min. 20µl of 
each subcellular fraction and whole cell extract or 5x1010 vector capsids were loaded. A 5% 
stacking gel was used, whereas the percentage of the running gel was chosen according to 
the size of the proteins that should be detected. Electrophoresis was performed at 80-100V 
in 1x running buffer. 
After protein separation by SDS-PAGE the proteins were transferred to a nitrocellulose 
membrane (Hybond-ECL (Amersham Bioscience)) using a “BioRad Mini Trans-Blot 
Electrophoretic Transfer Cell” according to the manufacturer’s instructions. Blotting was 
performed over night at 20mA. 
After blotting, the membrane was blocked for 60min using 5% milk powder and 0.1% Tween 
20 in 1x PBS shaking at room temperature. The blocking solution was substituted with the 
primary antibody in a suitable dilution (B1 (1:10), anti-Akt (1:1000), anti-Lamin B (1:500), 
anti-Rab5 (1:1000)) and left for 60min shaking at room temperature. After three washing 
steps with 0.1% Tween 20 in 1x PBS shaking for 5min at room temperature, the solution on 
the membrane was replaced by the secondary antibody (anti-mouse IgG-HRP diluted 
1:2000-1:5000 in blocking buffer, anti-goat IgG-HRP and anti-rabbit IgG-HRP 1:2000) and 
left for 60min shaking at room temperature. After three washing steps like before, 
0.125ml/cm2 membrane of substrate solution for the peroxidase-conjugated secondary 
antibody (Western LightningTM Chemiluminescence Reagent Plus (PerkinElmer)) was added 
to the membrane. After removing the substrate solution, a radiographic film was exposed to 
the membrane and subsequently the film was developed. 
 
Laemmli buffer (6x):  60mM Tris pH 6.8 
9.3mg/ml DTT (Dithiothreitol) 
12% SDS 
47% Glycerol (v/v) 
0.6mg/ml Bromophenol Blue 
 
Running buffer: 25mM Tris Base 
   192mM Glycin 
   0.1% SDS 
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5% stacking gel (2ml):  1.4ml distilled water 
0.33ml acrylamide stock solution, 30% (w/v) 
0.25ml 1.0M Tris (pH 6.8) 
0.02ml 10% sodium dodecyl sulfate (SDS) 
0.02ml 10% ammonium persulfate (APS) 
2µl N,N,N,N-Tetramethylethylenediamine (TEMED) 
 
8% resolving gel (5 ml):  2.3ml distilled water 
1.3ml acrylamide stock solution, 30% (w/v) 
1.3ml 1.5M Tris (pH 8.8) 
0.05ml 10% SDS 
0.05ml 10% APS 
3µl TEMED 
 
12% resolving gel (5 ml): 1.6ml distilled water 
2.0ml acrylamide stock solution, 30% (w/v) 
1.3ml 1.5M Tris (pH 8.8) 
0.05ml 10% SDS 




To determine the capsid titer of rAAV vector preparations, an ELISA was performed using 
the anti-capsid antibody A20.  
AAV capsid standard and samples (diluted in 100µl 1x PBS) and 100µl 1x PBS (negative 
control) were pipetted separately into a 96-well plate. Eight serial dilutions were prepared of 
all samples to obtain concentrations in a linear range. The plate was sealed with parafilm and 
incubated over night at 4°C. 
The next day, the contents of the plate were discarded, each well was filled with 200µl 
washing buffer, incubated for 5sec and emptied again. This washing step was repeated nine 
times. Afterwards, the wells were incubated with 200µl blocking buffer for 1h at room 
temperature. Then, wells were incubated with 100µl of anti-capsid antibody A20 (diluted 1:10 
in blocking buffer) for 1h at room temperature. Three washing steps were repeated as 
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described above. The secondary antibody (anti-mouse IgG-biotin, diluted 1:25000 in blocking 
buffer) was pipetted into each well and incubated for 1h at room temperature. Another three 
washing steps were performed as described before and 100µl of streptavidin peroxidase 
conjugate (diluted 1:500 in blocking buffer) were pipetted into each well and incubated for 1h 
at room temperature. After another three washing steps and two additional washing steps 
with 200µl of distilled water, 100µl of substrate solution were added into each well. Incubation 
was performed for 5-15min at room temperature. Colour reaction was then stopped by 
adding 50µl of 1M H2SO4 into each well and the intensity of the colour reaction was 
measured at 450 nm using a photometer. 
 
Washing buffer:  0.05% Tween 20 in 1x PBS 
 
Blocking Buffer:  washing buffer containing 3% BSA and 5% sucrose 
 
Substrate solution:  1mg TMB (3,3’, 5,5’-Tetramethylbenzidine) 
100µl DMSO 
10ml 0.1M NaOAc pH 6.2 
1µl 30% H2O2 (added just before use) 
 
2.2.4 Eukaryotic cell culture 
2.2.4.1 Cultivation of cells 
HeLa, HEK293 and HepG2 were maintained in Dulbecco`s modified Eagle`s medium 
(DMEM) with GlutaMAXTM-I, supplemented with 10% fetal calf serum, 100 U/ml penicillin, 
100 mg/ml streptomycin. BLM and K-562 were maintained in RPMI-1640 medium with 
GlutaMAXTM-I, supplemented with 10% fetal calf serum, 100U/ml penicillin, 100mg/ml 
streptomycin. All cell lines were maintained in a humidified incubator with 5% CO2 at 37°C. 
 
2.2.4.2 Drug treatment 
Chlorpromazine (10µg/ml final concentration) or Genistein (200µM final concentration) was 
used to inhibit clathrin- or caveolin-mediated endocytosis. Bafilomycin A1 (100nM final 
concentration) is a specific inhibitor of the vacuolar ATPase and was used to inhibit 
endosomal maturation. MG-132 (carbobenzoxy-Leu-Leu-leucinal, 10µM final concentration) 
was used to inhibit the 26S proteasome. All drugs were added to cells 30min prior to 
transduction and remained present until transduction was stopped by washing or trypsin 
treatment.  




2.2.4.3 Trypsin treatment 
Cells were washed with PBS, then trypsin (0.5g/l) was added in an amount that covered the 
bottom of the plate or flask, followed by an incubation at 37ºC (time depending on the cell 
line). When the cells detached from the plate, reaction was stopped by adding medium 
containing 10% FCS. 
 
2.2.4.4 Counting, seeding and passaging 
After washing and trypsin treatment, cells were either passaged or seeded. For passaging, 
cells were diluted 1:10 in a new flask containing fresh medium pre-warmed to 37°C. Slight 
agitation of the flask should ensure homogenous distribution of the cells. Prior to seeding, 
cells were counted. 10µl of diluted cells were transferred into a “Neubauer” chamber. The 
number of cells in each of the four squares (n) was counted and an average was built for 
more precise determination. The amount of cells in 1ml equals n x 104 x dilution factor. Cells 
were suspended in fresh medium, pre-warmed to 37°C, and homogenously distributed.  
 
2.2.4.5 Freezing and thawing cells 
Cells were trypsinized and pelleted at 500xg before resuspending them in freezing solution 
containing 90% FCS and 10% DMSO. Approximately 1x106 cells per 1ml suspension were 
added to each freezing vial. Immediately, the suspension was put on ice and then transferred 
to -80°C in an isopropanol containing freezing carrousel. The next day, cells were transferred 
to liquid nitrogen. 
For thawing cells, the freezing vial was taken out of the liquid nitrogen tank and transported 
on ice. Carefully, the suspension was thawed in a water bath at 37°C and the cells were 
transferred into a 50ml plastic tube containing pre-warmed medium before pelleting the cells 
at 500xg for 5min at room temperature in order to remove toxic DMSO. After resuspension in 
fresh medium, the cells were plated in culture dishes. 
 
2.2.4.6 DAPI staining 
HeLa cells seeded on 12mm coverslips inside 24-well plates were washed twice with 1x 
PBS. 4′,6-Diamidino-2-phenylindol (DAPI) was dissolved in sterile H2O at a concentration of 
1mg/ml. DAPI-solution was diluted to a final concentration 1µg/ml in methanol and distributed 
on the cells. Cells were incubated in the dark for 10-15min, then DAPI-solution was removed 
and cells were washed twice with 1x PBS. After embedding the cover slips in Vectashield 
mounting medium, samples were analyzed at a wavelength of 360nm using a fluorescence 
microscope. 
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2.2.5 Vector production and purification 
2.2.5.1 AAV vector packaging 
AAV particles were produced in HEK293 cells by the adenovirus-free production method 
using pXX6-80 to supplement the adenoviral helper functions [165]. 
Briefly, 7.5x106 HEK293 cells were seeded in 15cm2 cell culture plates. Twenty-four hours 
later, at an approximate confluence of 80%, medium was exchanged. Two hours afterwards, 
co-transfection was performed using the calcium phosphate method. Depending on the 
desired vector type, the following plasmids were used per 15 cm2 cell culture plate: 
 
For rAAV2 and rAAV peptide insertion mutants: 
7.5µg AAV helper plasmid (pRC, pRC99-A2, pRC99-B1, pRC99-C2 or pRC99-D5) 
7.5µg pGFP  
22.5µg pXX6-80 
 
For GFP-tagged rAAV peptide insertion mutants: 
7.5µg pRC VP2 k.o.-A2 (or pVP2k.o.-B1, pVP2k.o.-C2, pVP2k.o.-D5) 
7.5µg peGFP VP2.2-A2 (or peGFP VP2.2-B1, peGFP VP2.2-C2, peGFP VP2.2-D5) 
7.5µg pLuci 
22.5µg pXX6-80  
 
For each plate, 1ml CaCl2 (250mM) was mixed with the plasmid DNA, then 1ml HBS buffer 
(50mM HEPES, 280mM NaCl, 1.5mM NaP) was dropped onto the solution, incubated for 
2min and pipetted onto the plate while cautiously mixing with the medium. After 24h 
incubation at 37°C/ 5% CO2, medium was exchanged with DMEM containing only 2% FCS to 
reduce further cell division activity. The transfected cells were harvested and pelleted by low-
speed centrifugation on the following day (48h post transfection). The pellet was 
resuspended in lysis buffer (150mM NaCl, 50mM Tris-HCl (pH 8.5)) and the cellular and 
nuclear membranes were destroyed by repeated freeze and thaw cycles. To abolish genomic 
and plasmid DNA or RNA contaminants in the vector preparation, the suspension was 
treated with 50U/ml Benzonase for 30min at 37°C. Then, the suspension was centrifuged at 
3220xg for 30min at 4°C. The supernatant was taken off carefully and centrifuged again as 
mentioned before. 
 
2.2.5.2 Iodixanol gradient purification 
Discontinuous iodixanol gradient centrifugation was used to remove cellular debris. Full 
capsids were concentrated in the 40% phase of the iodixanol gradient. Vector suspension 
was inserted into an ultracentrifugation tube. The different phases of the iodixanol gradient - 
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starting with 15% - were sub-layered using a syringe connected to an Amersham 
Biosciences Pump P-1. 8ml, 6ml, 5ml and 6ml of the respective solutions were applied to a 
35ml ultracentrifugation tube. The tube was filled with PBS/MgCl2 (1mM)/KCl (2.5mM), 
closed and centrifuged at 63000rpm for 2h at 4°C (Sorvall Ultracentrifuge OTD Combi). 
Subsequently, the 40% iodixanol phase was harvested. 
 
 15%  25%  40%  60% 
10x PBS 5ml  5ml  5ml  - 
1M MgCl2 50µl  50µl 50µl 50µl 
2.5M KCl 50µl  50µl  50µl  50µl  
5M NaCl 10ml  - - - 
Optiprep 12.5ml  20ml  33.3ml  50ml 
0.5% Phenolred 75µl  75µl  - 25µl 
H2O ad 50ml  ad 50ml  ad 50ml  ad 50ml  
 
2.2.5.3 Vector titration 
For extraction of the vector genome from viral particles, the DNeasy Blood & Tissue Kit 
(QIAGEN) was used according to the protocol for “Isolation of Total DNA from Cultured 
Animal Cells”. Starting with 10µl of the vector preparation mixed with 190µl PBS, DNA was 
finally eluted in 200µl 10mM Tris/HCl pH 8.5. 
The genomic titer was then determined by qPCR as described before (2.2.2.9). To quantify 
the amount of vector genomes within the extracted DNA, defined dilutions (1x108 to 1x105 
genomic particles (g.p.)/µl) of the respective transgene-encoding plasmid were prepared and 
used as absolute standards in the qPCR. 
 
2.2.6 Selection of rAAV peptide insertion mutants 
2.2.6.1 Heparin affinity chromatography 
Prior to selection, the coupled AAV peptide display library was divided into an HSPG-binding 
and HSPG-non-binding fraction by heparin affinity chromatography. Using the Amersham 
Biosciences Pump P-1, a HiTrap Heparin Affinity Column was equilibrated with 1x PBS/ 
MgCl2 (1mM)/ KCl (2.5mM) (abbrev. PBS M/K).  Two ml of AAV peptide display library were 
diluted 1:3.5 with PBS M/K and applied to the column. The flow-through was collected and 
applied again after washing the column with PBS M/K. The flow-through was collected again 
and designated “HSPG-non-binder library”. After another washing with PBS M/K the Heparin-
bound particles were eluted with PBS M/K containing 1M NaCl. The eluate was designated 
“HSPG-binder library”. Subsequently, both fractions were concentrated by discontinuous 
iodixanol gradient centrifugation and the genomic titer was determined as described before 
(2.2.5.2, 2.2.5.3). 




2.2.6.2 Selection of rAAV peptide insertion mutants on K-562 cells 
Selection procedure was carried out according to a protocol established in our laboratory 
[171]. 7.5x106 K-562 cells were seeded in 75cm2 flasks and transduced with 103 genomic 
particles of HSPG-non-binder library. Separately, 7.5x106 K-562 cells were transduced with 
103 genomic particles of HSPG-binder library. Two hours post transduction, AAV was 
removed; cells were washed twice with PBS, resuspended in RPMI-1640 and superinfected 
with 10µl of wild-type adenovirus type 5 (wtAd5). Two hours post infection, wtAd5 was 
removed from the cells and cells were washed like before. Cells were maintained in RPMI-
1640 for 48h at 37°C. Fourty-eight hours post infection, cells were harvested, resuspended in 
300µl lysis buffer (150mM NaCl, 50mM Tris-HCl (pH 8.5)) and viral progeny was obtained by 
three cycles of freeze and thaw. Adenovirus was heat-inactivated at 60°C for 30min. After 
each selection round, the genomic titer of these preparations was monitored by qPCR using 
the wtAAV protocol (2.2.2.9) and the preparations were used for further selection rounds. 
Selection pressure was raised by reducing the initial amount of virus applied to the cells from 
1000g.p./cell in the first selection round to 10g.p./cell in the second selection round to 
1g.p./cell in the third selection round. 
 
2.2.7 Cell transduction by rAAV vectors 
2.2.7.1 Quantification of vector entry efficiency  
Twenty-four hours prior to transduction, cells were seeded sub-confluently in 12-well plates. 
Cells in one well were counted before cells were incubated with rAAV2 or rAAV peptide 
insertion mutants in 500µl of medium. To allow vector binding, 60min incubation on ice was 
performed before cells were shifted to 37°C and 5% CO2. Cells were harvested at different 
points in time. The supernatant was removed and cells were washed with 1x PBS. Then, 
cells were extensively treated with trypsin to ensure the removement of membrane-bound 
vector particles and to detach cells from the plate as previously described [9],[10],[172]. Cells 
were pelleted at 500xg for 5min, washed twice with 1x PBS and total DNA was isolated as 
described before (2.2.2.5). Relative quantification of vector genomes (GFP) and reference 
gene (Plat) was performed by qPCR as previously depicted (2.2.2.9). 
 
2.2.7.2 Quantification of vector genome transcripts 
Twenty-four hours prior to transduction, cells were seeded sub-confluently in 12-well plates. 
Cells in one well were counted before cells were incubated with rAAV2 or rAAV peptide 
insertion mutants as described above (2.2.7.1). One hour p.t., medium was changed to 
DMEM containing 3% anti-capsid antibody A20 in order to prevent so far unbound vector 
particles from binding to the cell. At different points in time, cells were harvested by removing 
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the supernatant, washing twice with 1x PBS and lysing the cells in buffer ATL (component of 
the Qiagen RNeasy Mini Kit) containing 1% β-mercaptoethanol. Total RNA was extracted 
and cDNA was synthesized as described before (2.2.2.6, 2.2.2.7). Relative quantification of 
vector genome transcripts (GFP) and reference transcript (AlasI) was performed by qPCR as 
previously depicted (2.2.2.9). 
 
2.2.7.3 Cell transduction assay 
Twenty-four hours prior to transduction, cells were seeded sub-confluently in 12-well plates. 
Cells in one well were counted before cells were incubated with rAAV2 or rAAV peptide 
insertion mutants as described above (2.2.7.1). In case of Chlorpromazine, Bafilomycin or 
Genistein treatment, transduction was stopped after 2h by washing with 1x PBS, trypsin 
treatment and re-seeding the transduced cells in fresh medium. Cells treated with MG-132 
were washed with 1x PBS 4h p.t. and fresh medium was added. If the experiment was 
performed with adjusted intracellular vector particles, with the exception of MG-132 
treatment, medium was changed to DMEM containing 3% anti-capsid antibody A20 1h p.t. to 
avoid further cell entry of vector particles. Twenty-four hours p.t., cells were harvested, 
washed and resuspended in 1x PBS. Since the vectors used for transduction carried GFP as 
a transgene, the percentage of transduced, GFP-expressing cells was determined by flow 
cytometry using a BD FACS Calibur system. According to the wavelength of GFP, samples 
were measured in the FITC channel. A minimum of 5000 cells was counted for each sample. 
Background fluorescence was set to 1%. 
 
2.2.7.4 Heparin competition assay 
Twenty-four hours prior to transduction, cells were seeded sub-confluently in 12-well plates. 
Cells in one well were counted and rAAV vectors were incubated with concentrations 
between 0.02 IU/ml and 400 IU/ml of soluble Heparin (25000IU/ml) in 500µl of medium for 
30min at room temperature. Then, the mixture was applied to the cells. Twenty-four hours 
p.t., cells were harvested, washed and resuspended in 1x PBS. The percentage of GFP-
expressing cells was determined by flow cytometry as described before (2.2.7.3). 
 
2.2.7.5 Quantification of vector genomes in subcellular fractions 
Twenty-four hours prior to transduction, HeLa cells were seeded sub-confluently in 10 cm2 
cell culture plates. Cells in one plate were counted before cells were incubated with rAAV2 or 
rAAV peptide insertion mutants as described above (2.2.7.1). One hour p.t., medium was 
changed to DMEM containing 3% anti-capsid antibody A20 in order to prevent so far 
unbound vector particles from binding to the cell. Two hours p.t., cells were harvested. The 
supernatant was removed and cells were washed with 1x PBS. Then, cells were extensively 
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treated with trypsin to remove membrane-bound vector particles and to detach cells from the 
plate. Cells were pelleted at 500xg for 5min and washed twice with 1x PBS. Then, 
subcellular fractionation was performed using the Qproteome Cell Compartment Kit 
(QIAGEN) according to the protocol for “Subcellular Fractionation of Cultured Cell Sampes”. 
Briefly, cells were resuspended in cytosol extraction buffer. After centrifugation, the 
supernatant was collected as the cytosolic fraction. The pellet was resuspended in 
membrane extraction buffer to separate the membrane fraction in the supernatant. The pellet 
was further resuspended in nuclear extraction buffer. Benzonase treatment was not 
performed like in the manufacturer’s protocol to maintain non-denaturating conditions for free 
vector genomes inside the nucleus. After centrifugation, the supernatant was collected as the 
nuclear fraction. The fractions were divided for further analysis of DNA and protein. 200µl of 
the cytosolic, membrane and nuclear fraction were used to extract DNA as described before 
(2.2.2.5). Prior to DNA extraction, 2µg of pLuci plasmid DNA was added to each fraction to 
monitor the accuracy of downstream procedures. Relative quantification of vector genomes 
(GFP) and reference gene (Luciferase) was performed by qPCR as previously depicted 
(2.2.2.9). To determine the purity of fractionation, proteins were concentrated from the 
fractions put aside for protein analysis using acetone precipitation (2.2.3.2). Subsequently, 
proteins from the cytosolic, membrane and nuclear fractions or from total HeLa cell lysat 
were analyzed by SDS-PAGE and western blot (2.2.3.3). 
 
2.2.7.6 Immunoflourescence assay of fluorescent-protein-tagged rAAV vectors 
Twenty-four hours prior to transduction, 4x104 HeLa cells were seeded onto 12mm coverslips 
inside 24-well plates. Cells in one well were counted before cells were incubated with 5x106 
capsids/cell of the respective fluorescent-protein-tagged vectors. To allow vector binding, 
60min incubation on ice was performed before cells were shifted to 37°C and 5% CO2. Four 
hours p.t., cells were washed twice with 1x PBS and fixed for 15min with 3% PFA in 1x PBS 
at room temperature. To quench remaining PFA, cells were washed with 50mM NH4Cl in 1x 
PBS and incubated with 50mM NH4Cl in 1x PBS for 30min at room temperature. Then, cells 
were washed twice with 1x PBS and permeabilized with 0.2% Triton X 100 in 1x PBS for 
5min at room temperature. After four washing steps with 1x PBS, samples were incubated 
with 0.2% gelatine in 1x PBS for 10min at room temperature to prevent unspecific binding of 
antibody. Incubation with the primary antibody (anti-Lamin B, diluted 1:50 in 0.2% gelatine in 
1x PBS) was carried out for 1h at room temperature. After washing and blocking as 
described before, cells were incubated at room temperature for 1h with the secondary 
antibody (anti-goat Cy5, diluted 1:50 in 0.2% gelatine in 1x PBS). Cells were washed again 
with 1x PBS, then, the cover slips were embedded in Vectashield mounting medium (Alexis) 
and examined using a confocal microscope (OLYMPUS FluoView FV1000). 




2.2.8 Statistical analysis 
To test for statistical significance, unpaired Student’s t-test was performed.  Two means or 
two groups of samples were defined as “significantly” different, if P was smaller than 0.05. In 
this case, the probability that the difference between to means or two groups of samples is 
due to chance is smaller than 5% and the probability that two means or two groups of 
samples are in fact “significantly” different is higher than 95%. Three gradations were used in 







3.1 Selection of AAV peptide insertion mutants on K-562 cells 
A previous study revealed that AAV peptide display carried out on HeLa cells results 
primarily in the selection of HSPG-binder mutants [Dissertation D. Goldnau, 2006]. In order 
to perform the proposed analysis, however, HSPG-binder and HSPG-non-binder mutants 
were required. Therefore, a cell line expressing only low levels of HSPG, the human chronic 
myelogenous leukemia cell line K-562 [92] was chosen as target for AAV peptide display 
selections. 
Prior to selection, the AAV peptide display library was coupled (PCT/EP2008/004366). This 
step is necessary to match the genotype with the phenotype of viral particles in the library. 
To carry out separate selections with a pool of AAV mutants, which are able to bind to 
HSPG, and a pool of AAV mutants enriched for non-HSPG-binding mutants, the coupled 
AAV display library was divided into a HSPG-binder and a HSPG-non-binder fraction by 
heparin affinity chromatography prior to selection (2.2.6.1). The genomic titers of the HSPG-
binder and HSPG-non-binder library were determined by qPCR and are indicated in Table 1. 
Three selection rounds on K-562 cells were performed with increasing selective pressure 
(2.2.6.2). Briefly, in the first selection round, K-562 cells were infected with 103 genomic 
particles (g.p.)/cell of HSPG-non-binder library and of HSPG-binder library, respectively. 
Helper virus fuction was provided by super infection with adenovirus 2h post AAV infection. 
Viral progeny was harvested, the genomic titer was measured by qPCR and the viral 
preparation was subjected to the next selection round. The second and third selection rounds 
were carried out exactly as described above with the exception that selection pressure was 
raised by reducing the virus to cell ratio from 1000 g.p./cell to 1 g.p./cell in the third selection 
round. As summarized in Table 1, viral progeny was produced in all three selection rounds. 
During the first selection round, progeny production with the HSPG-binder library was higher 
than with the HSPG-non-binder library (187-fold and 48-fold, respectively). The highest yield 
in viral progeny was obtained for both libraries in the second selection round, in which the 
selective pressure had been strongly raised (960-fold with HSPG-binder library, 1280-fold 
with HSPG-non-binder library). Comparing the viral yield again after the third selection round, 






















0 NB 3.7x107      
 B 1.8x109      
1 NB 1.2x109 7.5x106 1000 7.5x109 3.6x1011 48 
 B 4.7x109 7.5x106 1000 7.5x109 1.4x1012 187 
2 NB 3.2x108 7.5x106 10 7.5x107 9.6x1010 1280 
 B 2.4x108 7.5x106 10 7.5x107 7.2x1010 960 
3 NB 6.1x106 7.5x106 1 7.5x106 1.8x109 240 
 B 7.6x106 7.5x106 1 7.5x106 2.3x109 307 
Genomic titers of the initial HSPG-non-binder (NB) and HSPG-binder library (B) were determined prior 
to the first selection round (0). According to the number of cells and desired g.p./cell, the total amount 
of viral particles (“ancestors”) for the selection was calculated. The total amount of viral particles 
(progeny) was calculated from the genomic titer and the total volume (300µl) of viral progeny after 
each selection round. The relative progeny production is represented by the ratio of total viral progeny 
over total viral “ancestors”. 
 
 
After the third selection round viral DNA was amplified for subsequent cloning into the AAV 
helper plasmid pRC”Kotin” (2.2.2.8). 1.2kb were amplified surrounding the peptide insertion 
at amino acid position 587 (2.2.2.11.1). Fifty single viral clones were sequenced out of which 
21 readable sequences were obtained (Table 2). Several motives were apparently enriched 
by the selection: The sequence SNSVRSD was found in 29% of all sequences and was 
present in both HSPG-non-binder and HSPG-binder pool. Furthermore, sequences starting 
with NGI were prominent and found in both pools. RGD-containing sequences were 
exclusively observed in the HSPG-non-binder pool, whereas lysine-rich, positively charged 
sequences were mostly found in the HSPG-binder pool.  
 
Table 2: Sequences in HSPG-non-binder and HSPG-binder pool after the third selection round 
pool mutant sequence net charge 
HSPG-non-binder (NB) NB-A2, NB-A3, NB-H3, NB-6  SNSVRSD neutral 
 NB-H1 SDSVRSE neutral 
 NB-B1 NGIRRFD + 
 NB-C2, NB-E3 NGIRSFD neutral 
 NB-D1 RGDSLSA neutral 
 NB-E2 RGDSLSG neutral 




 NB-G2 RGDSLIG neutral 
 NB-E1 PADNGTG - 
 NB-H2 KGVRSFD + 
HSPG-binder (B) B-A5, B-H5 SNSVRSD neutral 
 B-E4 NGIRSFD neutral 
 B-F4 NGIGSLD - 
 B-B2 TGTTALK + 
 B-C5 TGSKELK + 
 B-D5 KGTKAPK +++ 
Sequences are given in one letter code. Normal letters represent neutral amino acids, bold letters 
represent charged amino acids. Net charge of the sequence is indicated in the far right column.  
 
 
A total of four sequences out of both pools were chosen for further analysis in comparison to 
rAAV2: SNSVRSD (NB-A2), NGIRRFD (NB-B1), NGIRSFD (NB-C2) and KGTKAPK (B-D5). 
NB-A2 was chosen due to its abundance in the pool of sequences, NB-B1 and NB-C2 
because they differ in only one amino acid and thereby in overall charge. B-D5 was picked 
because of its high positive charge which is likely to confer HSPG-binding ability to the 
mutant. In this work, the four mutants chosen will be referred to as A2, B1, C2 and D5.  
 
Single-stranded, 5’-phosphorylated oligonucleotides of the four insertion sequences N-
terminally flanked by the amino acids ASA and C-terminally flanked by the amino acids AA 
were used for subsequent cloning into the AAV helper plasmid pRC99. Annealing of single-
stranded oligonucleotides led to double-stranded oligonucleotides possessing MluI and AscI 
sticky-ends for ligation into pRC99 (2.2.2.11.2).  
 
The four mutants A2, B1, C2 and D5 in pRC99 as well as rAAV2 were packaged with single-
stranded vector genome conformation encoding for the reporter gene GFP to further 
investigate their characteristics (2.2.5.1). Genomic titers were determined by qPCR (2.2.2.9) 
and capsid titer by A20 ELISA (2.2.3.4). The capsid to genomic ratio was calculated to 
compare packaging efficiency [101] (Table 3). Packaging efficiency varied slightly between 
the different vector preparations but all rAAV peptide insertion mutants were packaged with 
an efficiency of <50, which is indicative of a wild-type AAV2 phenotype according to Kern and 





Table 3: Characterization of vector preparations 





capsid titer per 
µl 
capsid to genomic 
ratio 
rAAV2 / / 1.28x109 1.41x1010 11 
A2 SNSVRSD neutral 3.06x108 7.39x109 24 
B1 NGIRRFD + 6.59x108 1.21x1010 18 
C2 NGIRSFD neutral 3.15x108 6.03x109 19 
D5 KGTKAPK +++ 1.18x108 1.23x109 10 




3.2 Characterization of rAAV peptide insertion mutants regarding 
cell entry 
To study rAAV peptide insertion mutants in comparison to rAAV2 with respect to their cell 
interaction, HeLa rather than K-562 were chosen as target cells since HeLa cells are highly 
permissive for AAV2, and the key steps in AAV2 infectious biology have been characterized 
on HeLa cells [9], [135], [136], [151]. To test if the selected rAAV peptide insertion mutants 
are capable of transducing HeLa cells, cells were incubated with 5x103 g.p./cell of the 
insertion mutants and rAAV2 for 24h at 37°C. Then, the percentage of GFP-expressing cells 
was measured by flow-cytometry (Figure 8, grey bars). rAAV2 showed the highest 
transduction efficiency (86.8%), followed by B1 with 61.9%. For A2 and C2, transduction 
efficiencies of 55.1% and 48.1%, respectively, were observed. D5 showed the lowest 
transduction efficiency (34.2%). Since HeLa cells were successfully transduced by all four 
AAV peptide insertion mutants, the selection performed on K-562 cells in fact gave rise to 
tools that could subsequently be analyzed on a rAAV2-permissive cell line.  
 
3.2.1 Analysis of primary receptor binding ability by Heparin competition 
The first crucial step in a viral infection is to overcome the cellular membrane. rAAV2 makes 
its first contact with the cell by binding to its primary receptor HSPG [6]. In order to analyze 
whether the four rAAV peptide insertion mutants also bind to HSPG, a Heparin competition 
assay was carried out. Heparin is structurally closely related to heparan sulphate and can 
therefore be designated as a soluble analogue of HSPG. Hence, Heparin can bind to the 
viral capsid of AAV2, suppressing its ability to bind to HSPG on the cell surface in a 




To assess the ability of the four rAAV peptide insertion mutants to bind to HSPG, 5x103 
g.p./cell of the insertion mutants and rAAV2 were incubated for 30min with 20 IU/ml Heparin 
and subsequently transferred onto HeLa cells. Twenty-four hours later, the percentage of 
transduced cells was determined by flow cytometry (Figure 8). Cell transduction by rAAV2 
and D5 was blocked by the addition of Heparin (1.7% and 0.7% residual transduction), while 
B1 transduction was notably less affected (26.2% residual transduction). In contrast, addition 
of Heparin did not interfere with A2- and C2-mediated transduction. In line with our previous 
observation [103], when comparing the net charge of the inserted ligand to the outcome of 
the Heparin competition assay, it can be concluded that rAAV mutants displaying a positively 
charged peptide insertion (B1 and D5) bind to Heparin, and consequently to HSPG, while the 




Figure 8: Transduction efficiencies of rAAV2 and rAAV peptide insertion mutants in the 
presence or absence of soluble Heparin 
20 IU/ml soluble Heparin was incubated with 5x103 g.p./cell of rAAV vectors in medium for 30min at 
room temperature. The vector-heparin suspension or 5x103 g.p./cell of rAAV vectors without Heparin 
were added to HeLa cells and incubated at 37°C in a humidified CO2 incubator. GFP-expression was 
measured by flow cytometry 24h p.t. Values represent the mean of three independent experiments, 
error bars show s.e.m. To define statistical significance between transduction of untreated and 
Heparin-treated samples, Student’s t-test was performed. ***:P<0.0005; ns: not significant. 
 
 
To further characterize the interplay of B1 and D5 – the insertion mutants displaying a 































and D5 (5x103 g.p./cell) were incubated with increasing Heparin concentrations and 
subsequently incubated with HeLa cells. rAAV2 was used as a control. Twenty-four hours 
later, the percentage of transduced cells was determined by flow cytometry (Figure 9). The 
Heparin titration revealed different dose-responses of inhibition for all three vectors, hence, 
they differed in the half maximal inhibitory concentration (IC50) of Heparin, implying that the 
three vectors exhibit different affinities to Heparin: rAAV2 showed an IC50 of approximately 
0.8 IU/ml, while the IC50 of D5 was 10 times lower (0.08 IU/ml). For B1, even at the highest 
Heparin concentration, only a maximum of 60% inhibition and an IC50 of approximately 30 
IU/ml were observed. The higher IC50 of B1 explained its higher residual transduction at 20 




Figure 9: Inhibition of cell transduction by HSPG-binder vectors in the presence of increasing 
concentrations of Heparin  
Heparin at the indicated concentrations was incubated with 5x103 g.p./cell of rAAV2 and HSPG-binder 
mutants in medium for 30min at room temperature. The vector-Heparin suspension or 5x103 g.p./cell 
of rAAV vectors without Heparin were added to HeLa cells and incubated at 37°C in a humidified CO2 
incubator. GFP-expression was measured by flow cytometry 24h p.t. Values represent the mean of 

































3.2.2 Inhibition of clathrin-mediated endocytosis by Chlorpromazine 
The most prominent entry pathway taken by viruses is clathrin-mediated endocytosis [173]. 
Also AAV2 is endocytosed from the cell surface in a clathrin-dependent process after binding 
to receptors on the host cell plasma membrane [9-11]. To monitor, whether any of the 
peptide insertion mutants is internalized in a clathrin-dependent way, inhibitor studies with 
Chlorpromazine (CPZ) were carried out. CPZ is a substance leading to mis-assembly of 
clathrin lattices on endosomes and loss of coated pits from the cell surface by inhibiting the 
assembly of the clathrin adaptor protein AP2 [174]. To determine the effect of CPZ on cell 
transduction by the insertion mutants and rAAV2, HeLa cells were incubated with a final 
concentration of 10µg/ml CPZ for 30min at 37°C. The peptide insertion mutants and rAAV2 
were added in two different genomic particle numbers per cell: 5x103 and 2x103. After 1h 
incubation on ice to allow vector binding, tranduction was performed for 2h at 37°C in the 
presence or absence of CPZ. Transduction was stopped by trypsin treatment, cells were re-
seeded in fresh medium and transduction efficiency was measured by flow cytometry 24h p.t. 
(Figure 10A). In addition, CPZ-treated and untreated HeLa cells seeded on 12mm cover slips 
were incubated with 0.5mg/ml transferrin-Alexa Fluor® 488-conjugate to control the 
effectiveness of CPZ treatment, since transferrin is known to be taken up via clathrin-
mediated endocytosis [175]. After 1h incubation on ice and 2h at 37°C, cells were stained 
with DAPI and analyzed by fluorescence microscopy (Figure 10B and C). With 5x103 
g.p./cell, transduction efficiencies of rAAV2 and of the insertion mutants A2, B1 and C2 were 
significantly inhibited by the addition of CPZ, while no interference with D5-mediated 
transduction was observed (light grey and black bars). In contrast to the particle to cell ratio 
of 5x103 g.p./cell, transduction of HeLa cells with 2x103 g.p./cell of B1 was not significantly 
inhibited by CPZ, whereas transduction by rAAV2, A2 and C2 was significantly reduced. D5 
was again not affected by CPZ treatment (white and dark grey bars). The strongest inhibition 
by CPZ was observed for the HSPG-non-binder mutants: 67.6% and 72.0% inhibition for A2 
and C2, respectively, with 5x103 g.p./cell; 62.4% and 64.9% inhibition for A2 and C2, 
respectively, with 2x103 g.p./cell. rAAV2-mediated transduction was inhibited to about the 
same extent in both genomic particle numbers: 29.3% inhibition with 5x103 g.p./cell and 
33.1% inhibition with 2x103 g.p./cell. B1 was only sensitive to CPZ with 5x103 g.p./cell: 39.2% 
inhibition was observed in this case, while no significant change in transduction efficiency 
was seen for B1 with 2x103 g.p./cell. The transduction efficiency of D5 was not significantly 








Figure 10: Transduction efficiencies in the presence or absence of Chlorpromazine 
A: HeLa cells were incubated with or without 10µg/ml Chlorpromazine (CPZ) for 30min at 37°C prior to 
transduction. 5x103 g.p./cell (light grey and black bars) or 2x103 g.p./cell (white and dark grey bars) of 
rAAV vectors were added. One hour incubation on ice was followed by 2h at 37°C in a humidified CO2 
incubator. Transduction was stopped by trypsin treatment and re-seeding the cells in fresh medium. 
GFP-expression was measured by flow cytometry 24h p.t. Values represent the mean of six 
independent experiments, error bars show s.e.m. To define statistical significance between 
transduction of untreated and drug-treated samples, Student’s t-test was performed. ***:P<0.0005; 
**:P<0.005; ns: not significant. 
B and C: HeLa cells seeded on 12mm cover slips were incubated with or without 10µg/ml 
Chlorpromazine (CPZ) for 30min at 37°C. 0.5mg/ml Transferrin-Alexa Fluor® 488-conjugate in medium 
was added and incubated for 1h on ice. After 2h at 37°C, cells were washed, stained with DAPI and 
analyzed by fluorescence microscopy. Merged images of pictures obtained by excitation at 360nm and 
500nm are shown. Scale bars indicate 20µm. B: w/o CPZ, C: 10µg/ml CPZ  
20 µm 20 µm 
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3.2.3 Inhibition of caveolar endocytosis by Genistein 
As outlined above, rAAV2 is taken up by clathrin-mediated endocytosis. Similarly, the uptake 
of A2, C2 and B1 at a high particle number (5x103g.p./cell) seemed to rely on clathrin-coated 
pit formation. The entry route of D5 and B1 with 2x103g.p./cell, at which no inibition by CPZ 
was observed, remained unclear. Therefore, inhibitor studies with Genistein were performed.  
Genistein blocks caveolae-mediated internalization through inhibition of protein tyrosine 
kinases [176]. Caveolar endocytosis was described as another popular entry route used by 
members of the virus families Picornaviridae and Polyomaviridae, e.g. SV40 and coxsackie B 
virus, and was recently shown to be an alternative entry pathway of AAV5 into HeLa cells 
[14],[15],[173]. To monitor the consequence of Genistein treatment on cell transduction by 
rAAV vectors, HeLa cells were incubated with a final concentration of 200µM Genistein for 
30min at 37°C. 2x103g.p./cell of rAAV2 and the insertion mutants were added and incubated 
for 1h on ice. rAAV5, packaged with single-stranded GFP, was included in the analysis 
(vector kindly provided by N. Schuhmann). Subsequently, transduction was carried out for 2h 
at 37°C in the presence or absence of Genistein. Transduction was stopped by trypsin 
treatment, cells were re-seeded in fresh medium and transduction efficiency was measured 
by flow cytometry 24h p.t. (Figure 11). rAAV5 was the only vector inhibited by Genistein 
(39.6% inhibition), rAAV2 transduction was unaffected by Genistein, while for the peptide 
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HeLa cells were incubated with or without 200µM Genistein for 30min at 37°C prior to transduction. 
2x103 g.p./cell of rAAV vectors were added. One hour vector binding on ice was followed by 2h at 
37°C in a humidified CO2 incubator. Transduction was stopped by trypsin treatment and re-seeding 
the cells in fresh medium. GFP-expression was measured by flow cytometry 24h p.t. Values represent 
the mean of three independent experiments, error bars show s.e.m. 
 
 
3.2.4 Combining Heparin competition and inhibition of clathrin-mediated 
endocytosis by Chlorpromazine  
As shown in paragraph 3.2.2, cell transduction efficiency of rAAV2 and the HSPG-binder 
mutant B1 were significantly inhibited by Chlorpromazine. To analyze, whether the vectors 
can use either pathway for cell entry, a combined treatment with Heparin at the IC50 and CPZ 
was carried out. Aiming to inhibit transduction by rAAV2 about 50%, 5x103 g.p./cell of rAAV2 
were incubated with 0.8 IU/ml soluble Heparin for 30min. For 50% inhibition of B1-mediated 
transduction, 30 IU/ml Heparin were incubated with 5x103 g.p./cell of B1 for 30min (IC50 
values were chosen according to Figure 9). HeLa cells were treated with CPZ as described 
before (3.2.2). The vector-Heparin suspensions were either transferred onto untreated HeLa 
cells or HeLa cells pre-treated with CPZ. In case of pre-treatment with CPZ, the drug was 
added to the vector-Heparin suspension in a final concentration of 10µg/ml. After 1h 
incubation on ice, tranduction was performed for 2h at 37°C. Transduction was stopped by 
trypsin treatment, cells were re-seeded in fresh medium and transduction efficiency was 
measured by flow cytometry 24h p.t. (Figure 12). In the presence of CPZ, residual 
transduction efficiencies of 61.5% and 57.4% were observed for rAAV2 and B1, respectively, 
while Heparin reduced transduction efficiencies to 37.5% and 54.8% in case of rAAV2 and 
B1, respectively. The combined treatment with Heparin and CPZ resulted in a further 
decrease of transduction for both vectors: rAAV2 and B1 were inhibited to residual 
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Figure 12: Transduction efficiencies in the presence of Chlorpromazine, Heparin, 
Chlorpromazine and Heparin or in the absence of the substances 
HeLa cells were incubated with or without 10µg/ml Chlorpromazine (CPZ) for 30min at 37°C prior to 
transduction (drug-untreated: white and dark-grey bars; CPZ-treated: light-grey and black bars). 5x103 
g.p./cell of rAAV2 and B1 were added (white and light-grey bars). Heparin at the inhibitory 
concentration 50 [IC50] of each vector (rAAV2: 0.8IU/ml; B1: 30IU/ml) was incubated with 
5x103g.p./cell of the respective vector in medium for 30min at room temperature. The vector-Heparin 
suspension was added to either HeLa cells pre-treated with CPZ (black bars) or untreated HeLa cells 
(dark-grey bars). In case of pre-treatment with CPZ (black bars), the drug was added to the vector-
Heparin suspension in a final concentration of 10µg/ml. One hour incubation on ice was followed by 2h 
at 37°C in a humidified CO2 incubator. Transduction was stopped by trypsin treatment and re-seeding 
the cells in fresh medium. GFP-expression was measured by flow cytometry 24h p.t. Transduction 
efficiencies without CPZ or Heparin treatment were set to 100%. Values represent the mean of three 
independent experiments, error bars show s.e.m. 
 
 
3.2.5 Determination of cell entry efficiency  
Having studied the cell entry mode of rAAV2 and the peptide insertion mutants, the impact of 
the cell entry mode on entry efficiency into different cell types was analyzed. In order to be 
independent of the accomplishment of all further steps in viral infection, cell entry efficiency 
was determined by qPCR of intracellular vector particles. Besides HeLa cells, HEK293, BLM 
and HepG2 cells were assayed. Cells were incubated with 5x103 g.p./cell of rAAV2 and the 
insertion mutants for 1h on ice followed by 4h incubation at 37°C. Cells were harvested by 




before total DNA was extracted. To determine intracellular vector genomes, qPCR was 
performed for vector DNA (GFP) and the human single-copy gene Plat. Melting peak 
analysis was accomplished to proof specificity of PCR products. Normalization of target gene 
(GFP) to reference gene (Plat) was carried out and the normalized target/reference ratios of 
rAAV2 were set to 1 (Figure 13). rAAV2, B1 and D5, which are all able to bind to HSPG, 
entered HeLa cells with a significantly higher efficiency than the HSPG-non-binder mutants 
A2 and C2. Similarly, entry efficiency of rAAV2 and the HSPG-binder mutants B1 and D5 
was significantly higher in case of HEK293, BLM and HepG2 cells compared to A2 and C2 




Figure 13: Cell entry efficiencies of rAAV vectors into different cell lines 
HeLa, HEK293, BLM and HepG2 cells were incubated with 5x103 g.p./cell of rAAV vectors for 1h on 
ice to allow vector binding and subsequently shifted to 37°C and 5% CO2. Cells were harvested by 
trypsin treatment 4h p.t. and total DNA was isolated. Intracellular vector genomes (GFP) and the 
single-copy gene Plat were determined by qPCR. Normalization to Plat was performed and the 
normalized target/reference ratios of rAAV2 at 4h were set to 1. Values represent the mean of three 
independent experiments, error bars show s.e.m. Student’s t-test was performed for each cell line, 
revealing a significant difference (P<0.0001) between HSPG-binders (rAAV2, B1 and D5) as one 




































To monitor the course of cell entry of rAAV2 and the peptide insertion mutants into HeLa 
cells, intracellular vector genomes were determined at several points in time. HeLa cells 
were incubated with 5x103g.p./cell of rAAV2 and the insertion mutants for 1h on ice to allow 
vector binding followed by incubation at 37°C. Cells were harvested at 15min, 30min, 60min, 
2h and 4h p.t. by trypsin treatment to ensure removement of membrane-bound vector 
particles. Cells were washed and total DNA was extracted. qPCR was performed for vector 
DNA and Plat (single-copy gene). The normalized target/reference ratios of rAAV2 at 4h p.t. 
were set to 1 (Figure 14A). rAAV2 and the HSPG-binder mutants B1 and D5 showed similar 
cell entry rates (black lines, filled symbols). For the HSPG-non-binder mutants A2 and C2, a 
less efficient cell entry than that of the HSPG-binder mutants and rAAV2 was observed (grey 
lines, open symbols). One hour p.t., significantly more intracellular vector genomes were 
detected for the HSPG-binder mutants and rAAV2 compared to the HSPG-non-binder 
mutants (P=0.0003). Between 1h and 4h p.t., further particles of all vectors were internalized 
but the cell entry efficiency of the HSPG-non-binder mutants remained significantly lower 
than that of the HSPG-binder mutants and rAAV2.  
To find out, if an HSPG-non-binder vector known to bind to cellular integrins exhibits a similar 
cell entry rate to the HSPG-non-binder mutants A2 and C2, the course of cell entry was 
monitored for rAAV-RGD4C587 in comparison to rAAV2 [87]. This rAAV mutant carrying an 
RDG4C insertion peptide at position 587 was previously shown to bind to soluble αvβ3 and 
αvβ5 integrins and to transduce HeLa cells independent of HSPG via integrins 
[87],[177],[178]. Transduction of HeLa cells with 5x103 g.p./cell of RGD4C587 and rAAV2, 
DNA extraction, qPCR and normalization was performed exactly as described above (Figure 
14B). Compared to rAAV2, the course of cell entry of RGD4C587 was significantly less 
efficient (P=0.0004 at 1h p.t.; P<0.0001 at 4h p.t.), whereas cell entry rates of RGD4C587 
and the HSPG-non-binder mutants A2 and C2 were similar at all points in time (Figure 14A 







Figure 14: Cell entry efficiencies of rAAV2 and rAAV peptide insertion mutants 
HeLa cells were incubated with 5x103 g.p./cell of rAAV vectors for 1h on ice to allow vector binding and 
subsequently shifted to 37°C and 5% CO2. Cells were harvested by trypsin treatment at the indicated 
time points and total DNA was isolated. Intracellular vector genomes (GFP) and the single-copy gene 
Plat were determined by qPCR. Normalization to Plat was performed and the normalized 
target/reference ratios of rAAV2 at 4h were set to 1. Values represent the mean of three independent 
experiments; error bars show s.e.m.  
A: Student’s t-test revealed a significant difference (***:P<0.0005) between HSPG-binders (rAAV2, B1 


















































































3.3 Genetic fluorescence labelling of rAAV peptide insertion 
mutants 
Fluorescent proteins like GFP have been extensively used as fusion proteins to study 
intracellular trafficking and localization of proteins and viral particles [179],[180]. Previous 
studies showed that AAV2 incorporates the N-terminal fusion protein of GFP and VP2, 
thereby allowing a labelling of AAV2 particles [90],[91]. Further analyses carried out in our 
group revealed that additional fluorophores like CFP, dsRed and mCherry are tolerated in 
this position [Dissertation S. Stahnke, 2008]. Here, the peptide insertion mutants A2, B1, C2 
and D5 were labeled with GFP and compared to a mCherry-tagged rAAV2, since no antibody 
is available to distinguish between rAAV2 and the peptide insertion mutants. In order to 
generate vectors displaying the peptide insertion in all VP3 copies and, in addition, having a 
genetically fused GFP-tag at the N-terminus of VP2, the peptide insertions of the mutants A2, 
B1, C2 and D5 were cloned into peGFP-VP2.2 and pRC VP2 k.o. (2.2.2.11.3). These 
plasmids were used to package GFP-tagged insertion mutants. In parallel, a mCherry-tagged 
rAAV2 was packaged as a control. All vectors were packaged with Luciferase as transgene 
(2.2.5.1). Genomic titers were determined by qPCR (2.2.2.9), capsid titer by A20 ELISA 
(2.2.3.4) and the capsid to genomic ratio was calculated to compare packaging efficiency 
(Table 4). According to Kern and colleagues, wildtype packaging phenotype was observed 
for GFP-A2 and mCherry-rAAV2 with capsid to genomic ratios <50, whereas higher ratios 
were obtained in case of GFP-B1, GFP-C2 and GFP-D5, indicating reduced packaging 
efficiency [101].  
 
Table 4: Characterization of vector preparations: mCherry-tagged rAAV2 and GFP-tagged 
peptide insertion mutants 
vector genomic titer per µl capsid titer per µl capsid to genomic ratio 
mCherry-rAAV2 1.86x108 9.2x109 49.5 
GFP-A2 1.96x108 6.86x109 35 
GFP-B1 1.25x108 6.68x109 53.5 
GFP-C2 1.58x108 1.4x1010 87.5 
GFP-D5 5.32x107 3.3x109 62 
Titers were determined by qPCR and A20 ELISA, respectively. Capsid to genomic ratio indicates 






Western blot analysis of purified vector preparations was carried out to proof the 
incorporation of GFP or mCherry into the capsid of the respective vectors. 5x1010 capsids of 
mCherry-tagged rAAV2, the GFP-tagged insertion mutants and rAAV2 with unmodified 
capsid were separated by SDS-PAGE and blotted on nitrocellulose membrane. The three 
AAV capsid proteins were detected by B1 antibody that binds to the C-terminus of all capsid 
proteins. As depicted in Figure 15, a band of 100kDa was detected in case of all fluorescent-
protein-tagged rAAV vectors (the weaker bands of GFP-tagged A2 and GFP-tagged B1 
probably result from an overestimation of the respective capsid titers). This size 
corresponded to the fusion protein of VP2 (72kDa) and GFP or mCherry (both 27kDa). For 
unlabelled rAAV2, VP1 (90kDa), VP2 and VP3 (60kDa) were detected at a ratio of 
approximately 1:1:10.  
 
 
Figure 15: Western blot analysis of GFP-tagged insertion mutants and mCherry-tagged rAAV2 
5x1010 capsids of unmodified rAAV2 (wt), the GFP-tagged insertion mutants (GFP-A2, GFP-B1, GFP-
C2, GFP-D5) and mCherry-tagged rAAV2 were separated by SDS-PAGE using an 8% dissolving gel. 
After western blotting, the three capsid proteins were detected by B1, detecting the C-terminus of all 
three AAV capsid proteins (secondary antibody: Donkey anti-mouse IgG-HRP).  
 
 
To determine if the GFP-tagged insertion mutants were suited for intracellular visualization, 
HeLa cells were transduced with 5x106 capsids/cell. This capsid to cell ratio has previously 
been used to visualize GFP-tagged vectors inside transduced cells by fluorescence 
microscopy [91]. To promote binding of mCherry-tagged rAAV2 and the GFP-tagged 
insertion mutants, HeLa cells were incubated with the vectors for 1h on ice, followed by 4h at 
37°C. Transduction was stopped by washing and fixing the cells, followed by staining the 
nuclear lamina with anti-Lamin B. In Figure 16, multi-plane images obtained by confocal 
microscopy are shown. In case of mCherry-tagged rAAV2 and all GFP-tagged insertion 






Figure 16: Evaluation of GFP-tagged peptide insertion mutants and mCherry-tagged rAAV2  
HeLa cells were incubated with 5x106 capsids/cell of the respective fluorescent-protein-tagged vectors 
for 1h on ice and subsequently shifted to 37°C and 5% CO2. Four hours p.t., cells were washed and 
fixed. After permeabilization of the cells, nuclear lamina was stained with anti-Lamin B (secondary 
antibody: donkey anti-goat Cy5). Pictures show multi-plane images of HeLa cells transduced with 
mCherry-tagged rAAV2 (A), GFP-tagged A2 (B), GFP-tagged B1 (C), GFP-tagged C2 (D) and  GFP-























To analyze whether rAAV2 and the insertion mutants localize to the same intracellular 
region, co-transduction studies with mCherry-tagged rAAV2 were conducted exemplarily for 
the HSPG-binder mutant B1 and the HSPG-non-binder mutant C2. Single transductions with 
mCherry-tagged rAAV2, GFP-tagged B1 and GFP-tagged C2 were carried out for 
comparison. As described above, 1h incubation on ice was followed by 4h at 37°C. Then, 
transduced cells were washed, fixed and the nuclear lamina was stained with anti-Lamin B. 
Figure 17 shows pictures representing one slice (1µm) of a z-stack obtained by confocal 
microscopy. mCherry-tagged rAAV2 (A) as well as GFP-tagged B1 (B) and GFP-tagged C2 
(C) localized to the perinuclear area in single transductions. Co-transductions with mCherry-
tagged rAAV2 and GFP-tagged B1 (D-F) as well as mCherry-tagged rAAV2 and GFP-tagged 
C2 (G-I) revealed a perinuclear localization of rAAV2 and the peptide insertion mutants, 
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Figure 17: Intracellular localization of GFP-tagged B1, GFP-tagged C2 and mCherry-tagged 
rAAV2 after single or co-transduction  
HeLa cells were incubated with 5x106 capsids/cell of mCherry-tagged rAAV2, GFP-tagged B1 and 
GFP-tagged C2 for 1h on ice and subsequently shifted to 37°C and 5% CO2. For co-transduction, 
HeLa cells were incubated with 5x106 capsids/cell of mCherry-tagged rAAV2 and 5x106 capsids/cell of 
GFP-tagged B1 or 5x106 capsids/cell of mCherry-tagged rAAV2 and 5x106 capsids/cell of GFP-tagged 
C2. Four hours p.t., cells were washed and fixed. After permeabilization of the cells, nuclear lamina 
was stained with anti-Lamin B (secondary antibody: donkey anti-goat Cy5). Pictures show single-plane 
images representing one slice (1µm) of a z-stack. A-C: Transduction by mCherry-tagged rAAV2, GFP-
tagged B1 and GFP-tagged C2; D-F: Co-transduction by mCherry-tagged rAAV2 and GFP-tagged B1; 
G-I: Co-transduction by mCherry-tagged rAAV2 and GFP-tagged C2. Fluorescent dyes are indicated, 
scale bars represent 10µm. 
 
 
3.4 Characterization of rAAV peptide insertion mutants with 
respect to intracellular events 
 
3.4.1 Adjustment of  intracellular vector particles  
The HSPG-non-binder mutants A2 and C2 entered cells significantly less efficient than 
rAAV2 and the HSPG-binder mutants B1 and D5 (3.2.5). Hence, to compare intracellular 
events such as intracellular trafficking and transgene expression, an adjustment of 
intracellular vector particles was necessary [181]. Similar to the studies on re-targeted 
adenoviral vectors, intracellular vector particles of the HSPG-non-binder mutants A2 and C2 
were adjusted to those of rAAV2. Based on the relative numbers of intracellular vector 
genomes determined 1h p.t. (Figure 14), the genomic particle to cell ratio of A2 and C2, 
compared to rAAV2, was increased assuming that thereby the number of A2 and C2 that 
successfully enter the cell can be increased (Table 5). In details, compared to rAAV2, A2 and 
C2 showed 8.22 times and 12.48 times less intracellular vector genomes, respectively. 
Hence, to obtain comparable amounts of intracellular vector particles for all rAAV vectors, 
8.22 times more genomic particles per cell of A2 and 12.48 times more genomic particles per 
cell of C2 have to be applied compared to the genomic particles per cell of rAAV2. Since the 
entry efficiencies of B1 and D5 were not significantly different from rAAV2, no adjustment 










genomes 1h p.t. [rel.units] 
multiplier intracellular genomic 
particles  
rAAV2 5x103 0.699 / 5x103 
A2 5x103 0.085 8.22 8.22x5x103 
B1 5x103 0.690 1 1x5x103 
C2 5x103 0.056 12.48 12.48x5x103 
D5 5x103 0.854 1 1x5x103 
Based on cell entry efficiency 1h p.t., the multiplier between intracellular vector genomes of HSPG-
non-binder mutants (A2, C2) and intracellular vector genomes of rAAV2 was calculated in order to 
obtain comparable amounts of intracellular genomic particles. Since the entry efficiencies of B1 and 
D5 are not significantly different from rAAV2, the factor in this case is 1. 
 
In order to proof whether the above decribed assumption results in the desired adjustment of 
intracellular particles, HeLa cells were incubated with 5x103 g.p./cell of rAAV2, B1 and D5, 
8.22x5x103 g.p./cell of A2 and 12.48x5x103 g.p./cell of C2, which should correspond to 5x103 
intracellular genomic particles (i.g.p.)/cell. In addition, HeLa cells were incubated with 2x102 
i.g.p./cell of the rAAV vectors to test if the calculation for adjustment of intracellular particles 
is transferable to a lower particle to cell ratio. After 1h incubation on ice to allow vector 
attachment, transduction was performed for 1h at 37°C. Thereafter, cells were harvested by 
trypsin treatment to remove membrane-bound vector particles and cells were washed prior to 
DNA isolation. To determine intracellular vector genomes, qPCR was performed for vector 
DNA and Plat (single-copy gene). Normalization to Plat was carried out and the normalized 
target/reference ratios of rAAV2 were set to 1 (Figure 18). Without adjustment of intracellular 
particles, intracellular vector genomes of A2 and C2 1h p.t. were significantly different from 
rAAV2, whereas B1 and D5 were not significantly different from rAAV2 (Figure 18A). 
Compared to the initial situation, in case of 5x103 i.g.p./cell, no significant difference was 
observed between intracellular vector genomes of rAAV2 and any of the insertion mutants 
(Figure 18B). Also the adjustment to 2x102 i.g.p./cell revealed that none of the insertion 
mutants show a significant difference in intracellular vector genomes compared to rAAV2 






Figure 18: Adjustment of intracellular vector particles 
5x103 g.p./cell of rAAV vectors (A), rAAVs adjusted to 5x103 i.g.p./cell (B) or to 2x102 i.g.p./cell (C) 
were incubated with HeLa cells for 1h on ice to allow vector binding and subsequently shifted to 37°C 














































































































Intracellular vector genomes (GFP) and the single-copy gene Plat were determined by qPCR. 
Normalization to Plat was performed and the normalized target/reference ratios of rAAV2 were set to 1 
(B, C). A: data 1h p.t. from Figure 14. Values represent the mean of three (A), five (B) or four (C) 
independent experiments; error bars show s.e.m. To define statistical significance between rAAV2 and 
the four insertion mutants, Student’s t-test was performed. ***:P<0.0005; ns: not significant. 
 
 
3.4.2 Transduction efficiencies of rAAV vectors with adjusted intracellular 
particles 
In paragraph 3.2, transduction efficiencies of rAAV2 and the peptide insertion mutants was 
determined irrespective of different entry efficiencies of HSPG-binders and HSPG-non-
binders. Here, transduction efficiencies were monitored with adjusted intracellular vector 
particles. HeLa cells were incubated with 5x103 i.g.p./cell or 2x102 i.g.p./cell of rAAV2 and the 
insertion mutants for 1h on ice to promote vector binding followed by incubation at 37°C. One 
hour p.t., medium was exchanged to medium containing 3% anti-capsid antibody A20 in 
order to prevent so far unbound vector particles from binding to the cell and subsequent 
internalization. Transduction efficiency was measured by flow cytometry 24h p.t. (Figure 19). 
With 5x103 i.g.p./cell, rAAV2 transduced HeLa cells significantly more efficient (87%) than the 
HSPG-non-binder mutants A2 and C2, which showed similar transduction efficiencies (75.8% 
and 77.8%, respectively). Transduction efficiency of the HSPG-binder mutant B1 (68.5%) 
was significantly lower compared to rAAV2, but no statistical difference was detected 
between the three insertion mutants B1, A2 and C2. For the HSPG-binder mutant D5, the 
lowest transduction efficiency was observed (27%), which is significantly different from all 
other vectors (Figure 19, Table 6). With 2x102 i.g.p./cell, rAAV2 as well as the HSPG-non-
binder mutants A2 and C2 transduced HeLa cells with similar efficiencies: 25.1%, 17.1% and 
21% in case of rAAV2, A2 and C2, respectively. The HSPG-binder mutants B1 and D5 
showed significantly lower transduction efficiencies (7.8% and 2.9%, respectively) compared 
to rAAV2, A2 and C2. Furthermore, the poor transduction by D5 was revealed to be 





























Figure 19: Transduction efficiencies of rAAV vectors with adjusted intracellular genomic 
particles 
HeLa cells were incubated with 5x103 i.g.p./cell (black bars) or 2x102 i.g.p./cell (grey bars) of rAAV 
vectors for 1h on ice to allow vector binding and subsequently shifted to 37°C and 5% CO2. One hour 
p.t., medium containing 3% A20 was added. GFP-expression was measured by flow cytometry 24h 
p.t. Values represent the mean of three independent experiments, error bars show s.e.m. For 
statistical analysis, see Table 6. 
 
Table 6: Statistical analysis for transduction efficiencies of rAAV vectors with adjusted 
intracellular genomic particles  
A 5x103 i.g.p./cell       
  
P  
(vectors vs rAAV2) 
P  
(A2 vs C2) 
P  
(A2 vs B1) 
P  
(C2 vs B1) 
P  
(A2 vs D5) 
P  
(C2 vs D5) 
P  
(B1 vs D5) 
rAAV2 /       
A2 0.02 0.59 0.19  0.0007   
B1 0.0065  0.19 0.084   0.0017 
C2 0.012 0.59  0.084  0.0004  
D5 0.0002    0.0007 0.0004 0.0017 
 
B 2x102 i.g.p./cell       
  
P  
(vectors vs rAAV2) 
P  
(A2 vs C2) 
P  
(A2 vs B1) 
P  
(C2 vs B1) 
P  
(A2 vs D5) 
P  
(C2 vs D5) 
P  
(B1 vs D5) 
rAAV2 /       
A2 0.14 0.31 0.02  0.0045   
B1 0.011  0.02 0.0079   0.033 
C2 0.39 0.31  0.0079  0.0018  




A: Student’s t-test revealed significant differences between rAAV2 and all four rAAV peptide insertion 
mutants. A2 and C2 are not significantly different from each other and not significantly different from 
B1, but they are significantly different from D5. Furthermore, B1 is significantly different from D5. 
B:  Student’s t-test revealed significant differences between rAAV2, B1 and D5. A2 and C2 are not 
significantly different from rAAV2 and from each other but they are significantly different from B1 and 
D5. Moreover, B1 is significantly different from D5. 
 
 
3.4.3 Proteasome inhibition by MG-132 
Proteasome inhibitors are small molecule compounds that are able to specifically inhibit the 
activity of the proteasome. Most widely used are peptide aldehyds like carbobenzoxy-leu-leu-
leucinal (MG-132) which primarily inhibit the chymotrypsin-like activity of the proteasome 
[182]. Proteasome inhibitors have been previously shown to enhance AAV transduction in 
different cell types [136],[146],[144]. To analyze if the peptide insertion mutants and rAAV2 
are targets of proteasomal degradation, HeLa cells were incubated with a final concentration 
of 10µM MG-132 for 30min at 37°C. 2x102 i.g.p./cell of the insertion mutants and rAAV2 were 
added. After 1h incubation on ice to allow vector binding, tranduction was performed for 4h at 
37°C in the presence or absence of MG-132. Transduction was stopped by washing and 
addition of fresh medium. Transduction efficiency was measured by flow cytometry 24h p.t. 
(Figure 20). MG-132 treatment resulted in a significant enhancement of transduction in case 
of all vectors, albeit to slightly varying degree. Cell transduction by rAAV2 was increased by 
1.4-fold upon MG-132 treatment, while for the insertion mutants, a slightly stronger 
enhancement was detected. Cell transduction by B1 was doubled, whereas D5 showed 1.7-
fold higher transduction efficiency in the presence of MG-132. A2 and C2 were enhanced 






Figure 20: Transduction efficiencies in the presence or absence of MG-132  
HeLa cells were incubated with or without 10µM MG-132 for 30min at 37°C prior to transduction. 2x102 
i.g.p./cell of rAAV vectors were added. One hour incubation on ice was followed by 4h at 37°C in a 
humidified CO2 incubator. Transduction was stopped by removing the medium, washing the cells with 
PBS and addition of fresh medium. GFP-expression was measured by flow cytometry 24h p.t. Values 
represent the mean of three independent experiments; error bars show s.e.m. To define statistical 
significance between transduction of untreated and drug-treated samples, Student’s t-test was 
performed. ***:P<0.0005; *:P<0.05. 
 
 
3.4.4 Quantification of vector genome transcripts  
Transduction efficiencies with adjusted intracellular vector particles obtained by flow 
cytometry revealed that the HSPG-non-binder mutants A2 and C2 were superior to the 
HSPG-binder mutant D5 and – depending on the particle to cell ratio – also to B1, and 
reached similar transduction efficiencies as rAAV2 in a low particle to cell ratio (3.4.2). Vector 
uncoating was previously reported to limit the efficiency of transduction of hepatocytes 
mediated by AAV2 [183]. To analyze whether the weak cell transduction observed for B1 in a 
low particle to cell ratio and for D5 irrespective of the particle to cell ratio was due to an 
impaired vector uncoating, the onset of transgene expression – indicating a successful vector 
uncoating and delivery of vector genomes to the nucleus – was measured by quantifying 
vector genome transcripts at early points in HeLa cell transduction via qRT-PCR. Therefore, 
HeLa cells were incubated with 5x103 i.g.p./cell or 2x102 i.g.p./cell of rAAV2 and the insertion 

































p.t., medium was exchanged to medium containing 3% anti-capsid antibody A20 in order to 
prevent so far unbound vector particles from binding to the cell and subsequent 
internalization. Cells were harvested at 1h, 2h, 2.5h, 3h and 4h p.t. by lysis in β-
mercaptoethanol containing lysis buffer. Total RNA was extracted from the samples and 
cDNA was synthesized. To determine transcripts of vector genomes, qPCR was performed 
on cDNA for vector transcripts (GFP) and the human single-copy transcript AlasI. Melting 
peak analysis was accomplished to proof specificity of PCR products. Normalization to AlasI 
was carried out and the normalized target/reference ratios of rAAV2 at 3h p.t. were set to 1 
(Figure 21). One hour p.t., irrespective of the particle number, vector genome transcripts 
were detectable for all rAAV vectors, and from 2h p.t. onwards, transcript levels of all vectors 
increased (Figure 21A and B). Notably, already 2h p.t., more vector genome transcripts of 
rAAV2, A2, B1 and C2 were detected compared to D5. Similar to the results obtained by flow 
cytometry, with 5x103 i.g.p./cell, 4h p.t., rAAV2 showed the highest level of vector genome 
transcripts followed by the insertion mutants A2, B1 and C2. No significant difference was 
observed between rAAV2, A2, B1 and C2, whereas for D5, significantly fewer vector genome 
transcripts were detected 4h p.t. (Figure 21A). With 2x102 i.g.p./cell, the highest levels of 
vector genome transcripts were observed for rAAV2, A2 and C2 4h p.t., which were not 
significantly different. The HSPG-binder mutants B1 and D5 showed significantly lower 
vector genome transcript levels. Furthermore, significantly fewer vector genome transcripts 






Figure 21: Quantification of vector genome transcripts depending on time 
HeLa cells were incubated with 5x103 i.g.p./cell (A) or 2x102 i.g.p./cell (B) of rAAV vectors for 1h on ice 
followed by incubation at 37°C and 5% CO2. One hour p.t., medium containing 3% A20 was added. 
Cells were harvested at indicated time points and total RNA was isolated. After cDNA synthesis, 
transcripts of vector genomes (GFP) and the single-copy transcript AlasI were analyzed by qPCR. 
Normalization to AlasI was performed and the normalized target/reference ratios of rAAV2 at 3h were 
set to 1 and untransduced negative control was subtracted from the samples. Values represent the 
mean of three independent experiments; error bars show s.e.m.  
A: Student’s t-test revealed that rAAV2, A2, B1 and C2 are not significantly different from each other 























































































B: Student’s t-test revealed that rAAV2, A2 and C2 are not significantly different from each other but 
significantly different from B1 as well as from D5 at 4h p.t. Moreover, B1 is significantly different from 
D5. **:P<0.005; *:P<0.05; ns: not significant. 
 
3.4.5 Subcellular distribution of rAAV vectors  
As shown in paragraph 3.2.2, both B1 at a low particle to cell ratio and D5 were insensitive to 
treatment with CPZ, while rAAV2 was significantly inhibited by CPZ. Analysis of transduction 
efficiency and quantification of vector genome transcripts revealed that the HSPG-binder 
mutants B1 and D5 had both significantly lower transduction and transcript levels than rAAV2 
in case of cell transduction with 2x102 g.p. (3.4.2, 3.4.4). To assess whether the cell entry 
mode also influences the intracellular routing of rAAV vectors, the subcellular distribution of 
vector genomes was compared between rAAV2 and the HSPG-binder mutants B1 and D5. 
Since visualization of fluorescent-protein-tagged rAAV vectors is technically not possible with 
a lower particle to cell ratio than 5x106 capsids per cell (corresponding to about 105 g.p./cell), 
the Qiagen Qproteome Cell Compartment Kit was used for cell fractionation in order to 
quantify vector genomes in the cytosol, membranes and nuclei (2.2.7.5). HeLa cells were 
incubated with 2x102 g.p./cell of rAAV2 and the HSPG-binder mutants B1 and D5 for 1h on 
ice followed by incubation at 37°C. To prevent so far unbound vector particles from binding to 
the cell and subsequent internalization, medium was exchanged to medium containing 3% 
anti-capsid antibody A20 at 1h p.t. Two hours p.t., cells were harvested by extensive trypsin 
treatment to ensure the removement of unbound vector particles. Cells were washed and 
divided into cytosolic, membrane and nuclear fractions. After fractionation, DNA was 
extracted from equal volumes of the cytosolic, membrane and nuclear fraction. Prior to DNA 
extraction, Luciferase plasmid DNA was added to each fraction to monitor the accuracy of 
downstream procedures. To analyze vector genomes in subcellular fractions, qPCR was 
carried out for vector genomes (GFP) and reference gene (Luciferase). Normalization of 
target (GFP) to reference gene (Luciferase) was performed. In case of all three vectors, the 
majority of vector genomes were found in the membrane and nuclear fractions, whereas few 
vector genomes were observed in the cytosolic fraction (Table 7).  
 
Table 7: Subcellular distribution of rAAV vector genomes 2h post transduction 
  Distribution [%]  
 Cytosol Membranes Nuclei 
rAAV2 7.84 ± 2.32 36.63 ± 6.95 55.53 ± 7.08 
B1 5.18 ± 0.36 72.03 ± 4.63 22.8 ± 4.56 
D5 5.55 ± 0.12 73.7 ± 0.63 20.76 ± 0.62 





To compare the efficiency of intracellular routing of rAAV2 and the HSPG-binder mutants B1 
and D5, the ratio of vector genomes in membranes to vector genomes in nuclei was 
calculated (Figure 22A). The higher the ratio, the more vector genomes are detected in the 
membrane fraction. For B1 and D5, significantly higher ratios were determined compared to 
rAAV2, demonstrating that 2h p.t., a higher proportion of vector genomes of the HSPG-
binder mutants B1 and D5 was present inside membrane-coated cellular compartments (0.7, 
3.4 and 3.6 for rAAV2, B1 and D5, respectively). For rAAV2, the ratio of vector genomes in 
membranes to vector genomes in nuclei was smaller than one, indicating that more vector 




Figure 22: Subcellular distribution of rAAV2 and HSPG-binder mutants in cellular membranes 
and nuclei 
A: HeLa cells were incubated with 2x102 g.p./cell of rAAV vectors for 1h on ice to allow vector binding. 
Cells were subsequently shifted to 37°C and 1h p.t., medium containing 3% A20 was added. Two 
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each of the fractions previously spiked with Luciferase plasmid DNA and vector genomes (GFP) 
normalized to Luciferase (plasmid DNA) were determined by qPCR. Bars indicate the ratio of vector 
genomes in membranes over vector genomes in nuclei at 2h p.t. Values represent the mean of three 
independent experiments; error bars show s.e.m. Student’s t-test revealed a significant difference 
between rAAV2 and B1 as well as between rAAV2 and D5. ***:P<0.0005; *:P<0.05; ns: not significant. 
B: Proteins extracted from the cytosolic (C), membrane (M) and nuclear fractions (N) or from total cell 
lysat (T) were separated by SDS-PAGE. After western blotting, cytosolic and nuclear proteins were 




To determine the purity of fractionation, equal volumes of protein from the cytosolic, 
membrane and nuclear fractions or protein extracted from total HeLa cell lysat were analyzed 
by western blot (Figure 22B). Cytosolic proteins were detected by anti-Akt antibody, proteins 
in the membrane fraction by anti-Rab5 antibody and nuclear proteins by anti-Lamin B 
antibody. The upper blot shows detection by anti-Akt and anti-Lamin B, on the lower blot, 
detection by anti-Rab5 is depicted. Proteins were specifically detected in their corresponding 
fraction as well as in protein extract from total cell lysat with the exception of a weak band 
detected by Rab5 in the cytosolic fraction.  
 
 
3.4.6 Inhibition of endosomal maturation by Bafilomycin 
As shown in the previous paragraph, the HSPG-binder mutants B1 and D5 were mainly 
present in the membrane fraction of HeLa cells at 2h p.t., while for rAAV2, a higher 
proportion of vector genomes was observed in the nucleus at the same point in time. To 
monitor, whether rAAV2 and the insertion mutants B1 and D5 all rely on endosomal 
processing through early and late endosomes, inhibitor studies with Bafilomycin A1 were 
carried out. Bafilomycin is a specific inhibitor of the vacuolar ATPase in late endosomes and 
has been shown to block transport from early to late endosomes in HeLa cells [184]. To 
determine the effect of Bafilomycin on cell transduction by rAAV vectors, HeLa cells were 
incubated with a final concentration of 100nM Bafilomycin for 30min at 37°C. 5x103 g.p./cell 
of rAAV2 and the HSPG-binder mutants B1 and D5 were added. After 1h incubation on ice to 
allow vector binding, transduction was performed for 2h at 37°C in the presence or absence 
of Bafilomycin. Then, transduction was stopped by trypsin treatment, cells were re-seeded in 
fresh medium and transduction efficiency was measured by flow cytometry 24h p.t. (Figure 
23). In case of all three rAAV vectors, transduction was significantly reduced by the addition 
of Bafilomycin. rAAV2 showed 79.3% inhibition, while for B1 and D5, respectively, 91.2% and 






Figure 23: Transduction efficiencies of rAAV2 and HSPG-binder mutants in the presence or 
absence of Bafilomycin 
HeLa cells were incubated with or without 100nM Bafilomycin for 30min at 37°C prior to transduction. 
5x103 g.p./cell of rAAV2 and HSPG-binder mutants were added. One hour incubation on ice was 
followed by 2h at 37°C in a humidified CO2 incubator. Transduction was stopped by trypsin treatment 
and re-seeding the cells in fresh medium. GFP-expression was measured by flow cytometry 24h p.t. 
Values represent the mean of three independent experiments; error bars show s.e.m. To define 
statistical significance between transduction of untreated and drug-treated samples, Student’s t-test 



































In vivo gene therapeutic approaches depend on efficient and specific gene transfer vehicles 
in order to lower the vector dose to be applied, to achieve therapeutic levels of transgene 
expression and to minimize the risk of off-target transduction and toxic side effects. Adeno-
associated viral (AAV) vectors are among the leading gene therapy vector systems. 
However, like other vector systems, the broad tissue tropism and the accumulation of viral 
vector particles in the liver are obstacles for their in vivo application [7]. AAV vector targeting 
approaches have recently been developed to overcome these limitations. These approaches 
aim to redirect AAV from its natural tropism towards a desired target cell. Several small 
peptides genetically inserted into the AAV2 capsid at position 587 have been shown to 
mediate cell transduction independently of the AAV2 primary receptor heparan sulphate 
proteoglycan (HSPG), which is an important improvement regarding the restriction of vector 
tropism [54],[86],[93-95]. Furthermore, AAV display libraries with random peptide insertions 
at either 587 or 588 were applied to select capsid insertion mutants superior to AAV2 or 
natural AAV serotypes in transduction of the desired target cells or tissues in vitro and in vivo 
[95],[96],[185]. To date, little is known about the mechanisms of cell transduction that rely on 
a novel ligand-receptor interaction mediated by rAAV targeting vectors. This study provides 
not only insights into the uptake process of rAAV peptide insertion mutants, but also into the 
consequences for transgene expression.  
 
4.1 Vector-cell interactions at the plasma membrane 
Separate AAV display selections with an HSPG-binder library and an HSPG-non-binder 
library led to insertion mutants differing in sequence and net charge of the inserted ligand. 
The four mutants chosen for further analysis, namely A2, B1, C2 and D5, were packaged 
with an efficiency that indicates wildtype phenotype according to Kern and colleagues [101], 
revealing that that neither insertion interfered with capsid assembly or packaging. 
As observed previously, HeLa cells, which are highly permissive for rAAV2, were less 
efficiently transduced by most AAV targeting vectors [103]. In line, the four selected rAAV 
peptide insertion mutants were able to transduce HeLa cells, but rAAV2 clearly outperformed 
the mutants with respect to transduction efficiency.  
Efficient rAAV2-mediated cell transduction depends on primary receptor binding, since the 
ablation of the HSPG-binding motif by point mutations resulted in a loss of infectivity 
[101],[102],[87]. Targeting vectors with an insertion at amino acid position 453, which does 
not disrupt the HSPG-binding motif, achieved ligand-mediated cell transduction only if the 




peptides in 587 were used. Characterization of the insertion mutants concerning primary 
receptor binding revealed that two insertion mutants identified in the HSPG-non-binder pool, 
A2 and C2, were able to transduce HeLa cells independent of HSPG, while the insertion 
mutants B1 and D5 – like rAAV2 – were competed by the addition of Heparin. Moreover, 
those mutants that are independent of HSPG carry neutral insertions, while the HSPG-binder 
mutants possess positively charged insertion peptides. As previously reported, peptide 
insertions at amino acid position 587 interfere with the AAV2 HSPG-binding motif by 
separating two important arginine residues (R585 and R588) of this motif [101-103]. In 
accordance with a model postulated by our group [103], neutral peptide insertions which are 
not likely to bind to HSPG consequently mediate HSPG-independent cell transduction, 
whereas arginine-containing peptides can restore primary receptor binding ability, which 
seems to be the case for the HSPG-binder mutant B1. A Heparin titration further revealed a 
dramatic difference in dose-response relationship among the HSPG-binder vectors: D5, 
possessing three positive charges in the inserted sequence, showed a 10-times lower IC50 
than rAAV2 indicating a notably higher affinity to HSPG. Presumably, in case of D5, HSPG-
binding is mediated by electrostatic attraction of the positively charged ligand and the 
negatively charged cell surface proteoglycan. On the contrary, B1 was only partially affected 
by the addition of Heparin suggesting a lower affinity to HSPG of this insertion mutant.  
Attachment of AAV2 to HSPG results in a conformational change of the AAV2 capsid, which 
in turn leads to binding of the virus to its co-receptors [8],[131],[186]. AAV2 co-receptors, 
such as αvβ5 and α5β1 integrins, subsequently mediate endocytosis via clathrin-coated pits 
[9-11]. As yet, besides Heparin or peptide competitions, the uptake mechanism of rAAV 
targeting vectors has not been analyzed, but receptor-mediated endocytosis was suggested 
for vectors targeting integrins or CD13 [86],[92],[94],[87]. In this study, two entry pathways 
discussed for AAV – clathrin- and caveolae-mediated endocytosis [9-11],[14],[15] – were 
assessed by inhibitor studies. Correct formation of clathrin-coated pits was impeded by the 
addition of Chlorpromazine (CPZ) and resulted in a significant inhibition of transduction by 
rAAV2 and the two HSPG-non-binder mutants A2 and C2, strongly suggesting clathrin-
mediated uptake. In contrast, D5 – the high sensitivity HSPG-binder mutant – was not 
affected by CPZ treatment, pointing towards a different cell entry pathway. B1 was 
significantly inhibited by the addition of CPZ if the vector was applied in a high particle to cell 
ratio, while in a low particle to cell ratio, CPZ did not influence transduction efficiency. 
Obviously, in case of B1, vector dose was determining the uptake mechanism of the 
targeting vector. Maybe, the affinity of B1 to its receptor is not sufficient to achieve proper 
binding and numerous vector particles increase the probability for receptor binding and 
subsequent clathrin-dependent internalization. Furthermore, the interaction with HSPG could 




particles closer to their receptor, a phenomenon that was previously shown to be important 
for FGF-FGFR interaction and signalling [187]. 
Caveolar endocytosis was recently postulated to play an important role in the uptake of 
AAV5, which resulted in accumulation of viral particles in the Golgi compartment [14],[15]. 
Inhibitor studies with Genistein should reveal a potential participation of the caveolar pathway 
in the uptake of rAAV2 and the four peptide insertion mutants, especially B1 in a low particle 
to cell ratio and D5 that were not internalized clathrin-dependently. Apparently, neither rAAV2 
nor any of the insertion mutants rely on caveolar endocytosis, since the addition of Genistein 
did not lead to a reduction of cell transduction.  
In line with the current literature, rAAV2 was shown to be competed by soluble Heparin and 
internalized by clathrin-mediated endocytosis. The same was observed for the insertion 
mutant B1 with a high particle to cell ratio, even though it was less sensitive to Heparin. 
Structural rearrangements in the AAV2 capsid after primary receptor binding are believed to 
facilitate co-receptor binding; thus, HSPG- and co-receptor binding should happen one after 
another, explaining the dependency of rAAV2 on HSPG for infectivity. However, since 
transduction of rAAV2 and B1 was only partially reduced by inhibition of clathrin-mediated 
endocytosis, a portion of vector particles might have been forced to be internalized in 
complex with HSPG. Inhibition of clathrin-mediated endocytosis in combination with blocking 
rAAV2 and B1 vector particles with Heparin at their respective IC50 led to a notably higher 
inhibition compared to CPZ treatment alone. This observation showed that HSPG-binding 
was not only required to alleviate co-receptor binding but that rAAV2 and B1 are likely to be 
taken up via clathrin-coated pits and in complex with HSPG.  
The uptake mechanism of rAAV2 and the four peptide insertion mutants was assayed by 
inhibitor studies and Heparin competition: D5 used neither the clathrin-dependent pathway 
nor caveoli to transduce cells. The three-fold positively charged targeting insertion of D5 and 
its high sensitivity to Heparin strongly suggest a proteoglycan-dependent internalization of 
the vector, similar to cationic polymers [18],[23],[56]. B1 seems to be capable to enter cells in 
a clathrin- and/or in a proteoglycan-mediated fashion depending on vector dose. As 
mentioned above, at a high particle to cell ratio, B1 can be taken up by clathrin-mediated 
endocytosis, while at a low particle to cell ratio, B1 showed the same phenotype as D5, 
proposing proteoglycan-dependent internalization. The insertions of A2 and C2 equipped the 
respective mutants with the ability to transduce cells in an HSPG-independent, clathrin-
mediated fashion. Strikingly, rAAV2 was not exclusively internalized in a clathrin-dependent 
way, but, in addition, seemed to use its primary receptor HSPG not only for facilitation of co-
receptor binding but also for vector uptake. Obviously, the peptide ligands inserted into the 
AAV capsid determined the endocytotic pathway of the vectors, directing them either to 




depends only on HSPG (D5) or a combination of both ways of uptake (B1). Ligand-mediated 
change in vector internalization mode has recently been demonstrated for targeted 
transduction by a surface-engineered lentiviral vector and a liposomal nano-carrier, 
respectively [188], [189]. A Sindbis-virus-envelope-pseudotyped lentiviral vector was shown 
to enter cells via clathrin-mediated endocytosis – like native Sindbis virus – and not via direct 
fusion with the plasma membrane, as it is naturally the case for lentiviruses [188]. Similarly, a 
liposomal nano-carrier mainly taken up via macropinocytosis, was directed to caveolae- and 
clathrin-mediated uptake by incorporation of an IRQ-peptide ligand selected by phage 
display [189]. Futhermore, viral and non-viral vectors could successfully be targeted to 
distinct endocytic pathways, i.e. to the clathrin-dependent entry route by incorporation of 
ligands like transferrin or RGD-containing peptides [51],[60],[78], implying that the 
determination of the endocytic pathway by the targeting ligand is a common phenomenon in 
the field of vector targeting. 
 
In the current literature, transduction efficiency of targeted viral and non-viral vectors was 
predominantly assayed by measuring transgene expression using flow cytometry 
[57],[93],[94],[103],[87],[181],[188]. However, there are at least two major steps contributing 
to transduction efficiency: cell entry – or crossing the cellular membrane – and intracellular 
processing leading to transgene expression. Flow cytometry measurements can not provide 
detailed information about the uptake process itself. In this study, cell entry of rAAV2 and the 
peptide insertion mutants was therefore monitored as a separate event by quantifying 
intracellular vector genomes via qPCR.  
Transduction of human melanoma cells (BLM), human embryonic kidney cells (HEK293), 
human epithelial cervix adenocarcinoma cells (HeLa) and human epithelial hepatocellular 
carcinoma cells (HepG2) with rAAV2 and the peptide insertion mutants revealed significant 
differences in vector entry efficiency. While the HSPG-binder mutants B1 and D5 entered 
cells with comparable (HeLa and HEK293) or higher efficiency (BLM and HepG2) than 
rAAV2, the HSPG-non-binder mutants A2 and C2 were significantly less efficiently taken up 
into all cell lines tested. This difference in vector internalization strongly suggests that 
clathrin-mediated endocytosis of A2 and C2 is not as efficient as proteoglycan-dependent 
uptake of D5 or the combination of both entry pathways in case of rAAV2 and B1 in several 
human cell types. The reason for this could be the above mentioned association with the 
extracellular HSPG network, which catches the HSPG-binder mutants and rAAV2 in close 
proximity to the cellular membrane leading to a higher probability of subsequent vector 
uptake compared to A2 and C2, which solely rely on the interaction with their receptor for 




particle binding, leading to cortical actin rearrangement and particle engulfment [18],[23], 
which could well be a mechanism for enhanced uptake of HSPG-binder vectors.  
A time course analysis of rAAV vector uptake on HeLa cells further revealed different 
internalization rates for HSPG-binder vectors including rAAV2 and the HSPG-non-binder 
mutants. One hour p.t., similar amounts of vector genomes of HSPG-binder vectors and 
rAAV2 were detected inside the cell, whereas compared to rAAV2, 8.22- and 12.48-times 
less intracellular genomes of the HSPG-non-binder mutants A2 and C2, respectively, were 
detected. Since the cellular receptors of A2 and C2 are unknown, the uptake of a rAAV2 
vector with the well characterized RGD4C peptide inserted at position 587 was additionally 
analyzed. The model peptide RGD4C has been shown to bind selectively to αvβ5 and αvβ3 
integrins [177],[178]. HeLa cell transduction by rAAV2-RGD4C587 was recently observed to 
proceed in a HSPG-independent, peptide-mediated fashion [87]. Strikingly, though αvβ5 
integrin is highly expressed on HeLa cells [181], the internalization rate of RGD4C was 
significantly different from rAAV2, which uses the same integrin as a co-receptor. The time 
course of RGD4C-mediated cell transduction was similar to that of the HSPG-non-binder 
mutants A2 and C2, indicating that indeed, HSPG-binding enhances rAAV vector uptake. 
The previously published induction of conformational changes in the AAV2 capsid upon 
HSPG binding [8],[131],[186] is likely to allow endocytosis of rAAV2 but not of the insertion 
mutants due to their peptide displayed at the site of the HSPG-binding motif. However, the 
data obtained in this study provide strong evidence that also HSPG-binding per se is 
sufficient to induce the uptake of rAAV2 particles independent of the described structural 
rearrangements.  
 
Vector uptake is the first crucial step for efficient transgene delivery. The fact that cellular 
receptors have different expression profiles at the cell surface is of great importance for the 
comparison of ligand-mediated transduction by rAAV peptide insertion mutants in this study. 
In principle, it might have been possible that all receptors targeted by A2 and C2 were 
saturated when transducing HeLa cells with 5000 genomic particles per cell. This hypothesis 
can be rejected because transduction with 8.22- and 12.48-times higher genomic particles 
per cell of A2 and C2 than of rAAV2 was shown to compensate the significantly less efficient 
internalization of the HSPG-non-binder mutants compared to rAAV2. The calculation for the 
adjustment of intracellular particles based on 5000 g.p./cell was further shown to be 
transferable to a low particle to cell ratio of 200 g.p./cell, albeit with a higher variability. This 
kind of adjustment of intracellular vector particles has also been successfully applied in a 
recent study on adenoviral vectors [181]. Shayakhmetov and colleagues observed a reduced 
internalization rate of an adenoviral vector with an RGD motif deletion compared to an 




vector, the internalization rates of both vectors could be adjusted, which was a prerequisite to 
compare the intracellular trafficking of the two adenoviral vectors [181]. 
 
4.2 Intracellular vector fate 
Besides biochemical approaches using substances that specifically inhibit cellular processes  
[9],[11],[136],[137], the intracellular trafficking of AAV2 has been monitored by imaging 
studies. Visualization of AAV2 particles inside cells was achieved by antibody-staining of the 
viral capsid, by conjugating viral particles with fluorescent dyes and by genetically fusing 
fluorescent proteins to the N-terminus of the viral capsid protein VP2 [9],[91],[135],[127]. In 
this study, genetic incorporation of GFP into the capsid of rAAV mutants displaying peptide 
insertions at amino acid position 587 was shown to be feasible. However, the need of 5x106 
capsids per cell (corresponding to roughly 105 g.p./cell) to visualize fluorescent-protein-
tagged rAAV vectors impeded further imaging-based analysis, since substantial differences 
in vector uptake were observed already between 2000 and 5000 g.p./cell. Thus, in order to 
resolve rather low particle to cell ratios, the intracellular characteristics of rAAV peptide 
insertion mutants were assessed by molecular techniques. 
The intracellular routing of rAAV targeting vectors has not been assessed so far and some 
steps even remain unclear in case of AAV2. Recent studies on adenoviral vectors revealed 
that targeting different receptors either by constructing chimeric vectors or by inserting 
ligands into the capsid will lead to an altered intracellular trafficking compared to unmodified 
adenoviral vectors [35],[51]. The exchange of Ad5 fiber knob to Ad35 fiber knob resulted in a 
de-targeting of the vector from CAR to CD46, which caused a change in the intracellular 
trafficking route of the chimeric Ad5/Ad35 vector [35]. The combined shielding of vector 
particles and geneti-chemical coupling of transferrin to the Ad5 fiber HI-loop gave rise to 
efficient de- and re-targeting of the vector to the transferrin-pathway [51]. Even non-viral 
vectors, that naturally face the problem of entrapment in the endosomal compartment, could 
overcome this barrier by targeting a specific receptor: transgene expression could be highly 
increased by using an EGFR-targeted polyplex, suggesting more efficient gene delivery 
following receptor-mediated endocytosis [67]. 
Since differences in receptor usage and uptake mechanism were observed for the rAAV 
peptide insertion mutants analyzed in this study, an altered intracellular routing was 
assumed, similar to the above mentioned observations made for adenoviral and non-viral 
vectors. Knowing, that there was no receptor saturation in case of the HSPG-non-binder 
mutants A2 and C2 and that the adjustment of intracellular particles in a high and in a low 
particle to cell ratio was feasible, intracellular events were analyzed with vector particles 
having entered the cell in a synchronized manner. Starting with adjusted intracellular 




in cell entry efficiency has been corrected by raising the vector dose in case of the HSPG-
non-binder mutants A2 and C2. Transduction of HeLa cells with adjusted intracellular 
particles revealed that rAAV2 was most efficient. Contrary to transduction efficiencies 
obtained without balancing the differences in cell entry, the HSPG-non-binder mutants A2 
and C2 now reached the same transduction efficiency as B1 with a high particle to cell ratio 
and were even superior to B1 in a low particle to cell ratio. Remarkably, A2 and C2 
transduced HeLa cells with equal efficiency as rAAV2 in a low particle to cell ratio. D5 
showed significantly lower transduction efficiency than all other rAAV vectors. These 
observations indicate that intracellular routing following clathrin-mediated endocytosis 
resulted in more efficient transgene expression than intracellular trafficking subsequent to 
proteoglycan-dependent uptake. There are in principle three potential explanations for this 
phenomenon: First, those vectors that were internalized in a proteoglycan-dependent fashion 
could have been degraded to a higher extent than the vectors taken up via clathrin-mediated 
endocytosis. Second, vector uncoating could have been impaired in case of proteoglycan-
dependently internalized vectors, and third, vector internalization via clathrin-coated pits 
could have directed the endocytosed vectors to an exceeding intracellular trafficking route 
leading to efficient transgene expression compared to a less efficient intracellular routing of 
vectors internalized proteoglycan-dependently. 
With respect to the first explanation, AAV-mediated transduction was previously shown to be 
enhanced by inhibiting the proteasome which degrades ubiquitin-conjugated proteins in both 
cytosol and nucleus [136],[147],[151]. Here, the results obtained by inhibitor studies with MG-
132, a potent inhibitor of the 26S proteasome, revealed that not only rAAV2 was a target of 
proteasomal degradation, but also cell transduction mediated by the peptide insertion 
mutants was enhanced in the presence of MG-132. However, no considerable differences 
were observed between the strength of enhancement detected for HSPG-binder mutants and 
HSPG-non-binder mutants. This finding points out that less efficient transgene expression 
was not the consequence of increased proteasomal degradation of vectors internalized in a 
proteoglycan-dependent fashion. Noteworthy, Douar and colleagues figured out, that MG-
132 treatment led to an accumulation of single-stranded viral genomes that would possibly 
have been degraded in cells with an active proteasome [136]. Thus, by enriching single-
stranded viral genomes, the chance to become converted into a transcriptionally active 
double-stranded DNA template might be increased for rAAV2 as well as for the insertion 
mutants. 
Viral uncoating and the conversion of single-stranded viral genomes into the transcriptionally 
active double-stranded form are believed to be rate-limiting steps in the processing of AAV 
[183],[190]. In the absence of adenoviral genes, which were shown to facilitate the genome 




The conversion of viral ssDNA into dsDNA was shown to be accomplished 24h after infection 
[192]. Accumulation of viral genomes in a perinuclear area was observed between 15 and 
30min post infection and almost all transduced particles were nucleus-associated 3h p.i. 
[9],[11],[91]. Therefore, vector genome transcripts, appearing subsequent to intracellular 
vector trafficking and early after nuclear translocation of vector ssDNA and conversion to 
dsDNA, were assessed between 1 and 4h post transduction (p.t.). Since AAV was shown to 
accumulate in nuclear invaginations (tubular channels extending deeply into the 
nucleoplasm) during that time frame in HeLa cells [91], vector genome transcripts rather than 
intra-nuclear vector genomes were measured to exclude detection of virions that are not 
located inside the nucleus. Already 1h p.t., irrespective of the particle to cell ratio (5000 
i.g.p./cell or 200 i.g.p./cell), vector genome transcripts of all analyzed rAAV vectors were 
detectable. Although transcript levels of rAAV2, A2, B1 and C2 were higher than those of D5, 
transcripts of vector genomes increased in case of all rAAV vectors from 2h p.t. onwards. 
Since vector genome transcription happened in a similar time frame in case of rAAV2 and all 
peptide insertion mutants, it can be concluded that vector uncoating is not likely to be 
impaired in any of the insertion mutants. In line with the observations made for the analysis 
of transduction efficiency by flow cytometry, significant differences in vector transcript levels 
were observed between the different rAAV vectors 4h p.t. Transduction with 5000 i.g.p./cell 
did not result in different levels of vector genome transcripts for rAAV2, A2, B1 and C2. 
These four vectors had in common, that they were – at least partially – internalized via 
clathrin-mediated endocytosis. For D5, which was taken up clathrin-independently, 
significantly less transcripts of vector genomes were observed. Intriguingly, transduction with 
200 i.g.p./cell led to significantly different levels of vector genome transcripts between B1 and 
rAAV2, A2 and C2, which were not significantly different among each other. D5, as observed 
for the high particle to cell ratio, showed again significantly fewer transcripts of vector 
genomes compared to the other rAAV vectors. These observations support the hypothesis, 
that clathrin-mediated endocytosis of rAAV2, A2, C2 – and in a high particle to cell ratio also 
B1 – possibly directed the rAAV vectors to an efficient intracellular trafficking route that 
favours endosomal escape of vector particles, subsequent nuclear translocation of vector 
genomes and transgene expression. In contrast, proteoglycan-dependent uptake of D5 – and 
in a low particle to cell ratio also of B1 – may be inappropriate for endosomal escape of the 
insertion mutants, subsequently leading to less vector particles that can uncoat and whose 
vector genomes will be translocated to the nucleus and expressed. A possible explanation 
for this observation may be the electrostatic interaction of the two positively charged insertion 
mutants B1 and D5 with HSPG. D5 was shown to have a high sensitivity to Heparin and 
therefore the electrostatic interaction between D5 and HSPG is likely to be strong. B1 was 




The effect of the different HSPG-affinities could be that B1 can dissociate from HSPG in the 
endosome with a higher chance than the tightly bound D5. Consequently, B1 can escape the 
endosome more efficiently than D5 prior to lysosomal degradation, resulting in significantly 
higher transcript levels of B1 compared to D5, as it was observed with the low particle to cell 
ratio. As proposed for the highly positively charged insertion mutant D5, cationic DNA 
complexes, that are internalized following electrostatic interaction with HSPG were shown to 
be entrapped in endosomes and degraded in lysosomes [18],[57]. 
Regarding the third explanation mentioned above, i.e. an altered intracellular routing of the 
insertion mutants following proteoglycan-dependent uptake, a study on adenoviral vectors 
recently demonstrated that the exchange of Ad5 fiber knob to Ad35 fiber knob gave rise to a 
change in intracellular trafficking of the chimeric Ad5/Ad35 vector caused by internalization 
via CD46 instead of CAR [35]. Based on electron microscopic visualization of adenoviral 
particles within different intracellular compartments, Shayakhmetov and colleagues depicted 
the intracellular distribution of Ad and Ad5/Ad35 vectors. Contrary to Ad5, which already 
escaped from early endosomes by 2h p.i. and was found mostly in the cytosol or perinuclear 
space, the majority of chimeric vectors still resided in the endosomal compartment and only 
few chimeric vector particles were detected in cytosol and perinuclear space. Thus, the 
authors proposed that chimeric Ad5/Ad35 vectors internalized via CD46 were directed to a 
less efficient intracellular trafficking route that probably trapped the majority of viruses in 
late/lysosomal compartments. In this study, the hypothesis that clathrin-mediated 
endocytosis could be superior to proteoglycan-dependent uptake with respect to intracellular 
processing of vector particles was further tested by monitoring the intracellular distribution of 
rAAV2 vector genomes compared to B1 and D5. The subcellular fractionation of HeLa cells 
transduced either with rAAV2 or the insertion mutants B1 and D5 revealed a picture 
resembling the one obtained for adenoviral vectors. Like adenovirus, AAV escapes from the 
endosomal compartment but it is still a matter of debate whether the release of AAV takes 
place in an early or late endosomal stage [11],[135],[136],[138],[152]. After HeLa cell 
fractionation 2h p.t., a minor proportion of rAAV2, B1 and D5 vector genomes were found in 
the cytosol. rAAV2 vector genomes were detected in membrane and nuclear fractions with a 
ratio of 0.7 reflecting vector genomes in membranes over vector genomes in nuclei. Thus, 
the major portion of rAAV2 vector genomes was present inside nuclei 2h p.t. In contrast, 
significantly higher ratios were obtained for B1 and D5, indicating that vector genomes of the 
HSPG-binder vectors B1 and D5 predominantly resided inside membrane-coated cellular 
compartments 2h p.t. From the fractionation procedure itself, the endosomal compartment 
could not be distinguished from mitochondria and the endoplasmic reticulum, since they were 
collected in the same fraction, but from the current knowledge AAV would most likely be 




the endosome to a high extent and its vector DNA was nucleus-associated, while B1 and D5 
were mainly present in the endosomal compartment and only a minor part of their vector 
genomes entered the nucleus. Presumably, as observed for the Ad5/Ad35 vector and 
already suggested above, proteoglycan-dependent uptake of B1 and D5 led to an altered 
intracellular routing that did not favour endosomal escape of the two peptide insertion 
mutants. Although assessing the same problem with different methods, similar conclusions to 
the chimeric adenoviral targeting vector could be drawn for the rAAV insertion mutants 
impaired in efficient transgene expression in this study.  
Previous studies revealed that endosomal acidification is necessary for AAV2-mediated cell 
transduction [11],[136],[137]. Having proposed that the insertion mutants B1 and D5 could be 
directed to a distinct intracellular trafficking route, Bafilomycin A1-treatment should clarify, 
whether endosomal maturation is required for cell transduction by B1 and D5. A hint towards 
an involvement of endosomal maturation in intracellular trafficking following HSPG-
dependent uptake comes from the observation that HSPG degradation products could not be 
detected in Bafilomycin-treated rat hepatocytes, whereas in the absence of the drug, small 
HS fragments were found in lysosomes [193]. In addition to specific inhibition of the vacuolar 
ATPase, Bafilomycin was shown to block the transport from early to late endosomes, 
possibly by inhibiting the budding of vesicles from early endosomes [184],[193]. Strinkingly, 
cell transduction by rAAV2 as well as by B1 and D5 was almost completely abolished in the 
presence of Bafilomycin. This observation showed that endosomal maturation is crucial for 
intracellular processing of rAAV2 and the insertion mutants B1 and D5 irrespective of the 
endocytic mechanism. Recently, a clathrin- and caveolin-independent endocytic pathway has 
been identified in mammalian cells that was shown to be involved in the internalization and 
trafficking of cell surface proteoglycans and proteoglycan-binding ligands [56],[194]. The 
marker protein of this pathway, flotillin-1, has been identified in purified endosomes [194]. 
HSPG as well as HSPG-binding cationic polymers were shown to be internalized clathrin- 
and caveolin-independently, but dependent on flotillin-1 and dynamin. Subsequently, 
proteoglycan-bound ligands were found associated with flotillin-1-positive vesicles and 
efficiently trafficked to late endosomes.  Interestingly, this proteoglycan-dependent pathway 
did not require phosphatidyl-inositol-3 kinase (PI3K)-dependent sorting from early 
endosomes [56], whereas endocytosis and nuclear trafficking of AAV2 was reported to be 
controlled by Rac1 and PI3K activation [9]. Therefore, PI3K-dependent sorting might be an 
essential process leading to efficient intracellular processing of rAAV2 and most likely also of 
the insertion mutants internalized in a clathrin-mediated fashion. The proteoglycan-
dependent uptake of peptide insertion mutants might misguide the mutants to the flotillin-1 
pathway lacking PI3K-dependent sorting, which could lead to an accumulation of the 




To gain additional knowledge of differences in endosomal trafficking between rAAV2 and the 
rAAV peptide insertion mutants, different endosomal compartments will have to be 
fractionated and subsequently analyzed regarding the presence of rAAV vector genomes 
and a well defined endosomal marker like flotillin-1 or Rab proteins to identify individual 
pathways. 
 
4.3 Consequences of non-natural receptor binding: a model  
The results obtained in this study provide evidence for a model that depicts the intracellular 
consequences of novel ligand-receptor interactions mediated by rAAV peptide insertion 
mutants.  
As anticipated, the first interaction with the cell – i.e. primary receptor binding – differs 
between the analyzed rAAV vectors. In line with the current knowledge, rAAV2 attaches to its 
primary receptor HSPG, followed by co-receptor binding and clathrin-mediated endocytosis. 
The rAAV mutants A2 and C2 do not use HSPG as an attachment receptor but rely on their 
novel ligand-receptor interaction for clathrin-dependent uptake into the cell. Like rAAV2, the 
rAAV mutant B1 is able to bind to HSPG and to an additional internalization receptor, which 
mediates clathrin-dependent internalization of the vector. Since they differ in only one amino 
acid, B1 and C2 are likely to bind to the same or a very similar receptor. Contrary to C2, in 
case of B1, the affinity of the peptide ligand to its receptor may not be sufficient to trigger 
endocytosis. HSPG binding could enhance the ligand-receptor interaction of B1 or increase 
the chance of proper receptor binding by clustering numerous B1 vector particles at the cell 
surface. Consequently, if there are only few B1 vector particles present, the probability of 
being internalized via clathrin-mediated endocytosis decreases. The rAAV mutant D5 binds 
to HSPG with a high affinity and does not seem to use an additional receptor. The uptake of 
D5 and B1, if it can not be internalized in a clathrin-mediated fashion, is dependent on an 
electrostatic interaction of the positively charged peptide insertions of D5 and B1 with the 
negatively charged cell surface proteoglycans.  
Following clathrin-mediated endocytosis, rAAV2 – and probably also A2, B1 and C2 – are 
efficiently processed inside endosomes. It is believed that rAAV2 trafficking is dependent on 
the activation of Rac1 and PI3K, the latter of which is involved in endosomal sorting. All 
vectors that are internalized in a clathrin-dependent fashion seem to efficiently escape from 
the endosomal compartment and to be processed efficiently: compared to rAAV2, no 
significant differences in vector degradation and uncoating or transgene expression were 
observed. 
Proteoglycan-dependent internalization results in an altered intracellular routing of the rAAV 
mutants B1 and D5. Similar to vector trafficking following clathrin-mediated endocytosis, also 




maturation but it is not clear if both routes share an early endosomal compartment. The 
pathway following proteoglycan-dependent uptake of B1 and D5 is obviously not favourable 
for vector processing, since significantly more vector genomes are present in endosomes 
compared to rAAV2-mediated accumulation of vector genomes in the nucleus. Entrapment of 
B1 and D5 in endosomes could happen due to their electrostatic interaction with HSPG, 
leading to an impaired dissociation of the insertion mutants from the proteoglycan. Although 
with significantly lower levels compared to rAAV2, A2 and C2, vector genome transcripts of 
D5 and B1 appear in a similar time frame; hence, some of the internalized vector particles 
are able to escape from the endosome and to uncoat prior to lysosomal degradation. 
However, the question if B1- and D5-containing vesicles fuse with the pathway following 
clathrin-mediated endocytosis or if B1 and D5 escape from endosomes bypassing the sorting 






Figure 24: Model for the uptake of rAAV2 and rAAV peptide insertion mutants and the 
intracellular consequences 
Like rAAV2, the insertion mutants A2, B1 and C2 are internalized into the cell in a clathrin-mediated 
fashion. Following clathrin-mediated endocytosis, rAAV2 and the insertion mutants A2 and C2 are 
efficiently processed, probably via early and late endosomes similar to rAAV2, which is assumed to 
include PI3K-dependent sorting in an early endosomal compartment. Subsequent to vector uncoating, 
efficient transgene expression takes place inside the nucleus. If B1 is able to bind to its receptor, 
which is likely to occur in a high particle number, this positively charged insertion mutant is also taken 
up via clathrin-coated pits and consequently takes the same pathway as described for rAAV2, A2 and 
C2. B1, like the highly positively charged insertion mutant D5, can also be taken up into the cell 
without binding to an additional receptor, presumably via electrostatic interaction with HSPG. 
Following proteoglycan-dependent internalization, the insertion mutants are inefficiently processed. 
Only a small proportion of vector particles that will subsequently uncoat and deliver their genome to 





In conclusion, this study provides strong evidence that the peptide ligand inserted into the 
AAV capsid determines the cell entry mode of the insertion mutant and thereby the efficiency 
of transgene delivery to the nucleus. To achieve efficient intracellular processing, the 
insertion mutant – like rAAV2 – has to target a specific cellular receptor triggering clathrin-
mediated endocytosis. With regard to cell type specificity, the native tropism of AAV2, 
mediated by its HSPG-binding ability, should be ablated. Current studies carried out in our 
group point towards the achievement of a narrow tissue tropism by HSPG-non-binder 
mutants selected on primary human keratinocytes in vitro and BLM cells in vivo [John von 
Freyend and Sallach, unpublished data]. The in vivo selections further showed a redirection 
of the selected HSPG-non-binder mutants from the liver and other organs such as spleen, 
muscle, kidney and lung to the tumour [John von Freyend, unpublished data]. The re-
targeting of a HSPG-non-binder mutant with the property of efficient transgene delivery to the 
cell type of interest, while de-targeting the rAAV insertion mutant from non-target cells can 
indirectly achieve vector-dose reduction. Therefore, an AAV targeting vector mediating 
efficient and specific gene expression in vivo should carry a peptide insertion that both 
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